Tamoxifen
Based on 259 publication(s) in Google Scholar
Tamoxifen (ICI 47699) is an orally active, selective estrogen receptor modulator (SERM) which blocks estrogen action in breast cells and can activate estrogen activity in other cells, such as bone, liver, and uterine cells. Tamoxifen is a potent Hsp90 activator and enhances the Hsp90 molecular chaperone ATPase activity. Tamoxifen also potent inhibits infectious EBOV Zaire and Marburg (MARV) with IC50 of 0.1 μM and 1.8 μM, respectively. Tamoxifen activates autophagy and induces apoptosis. Tamoxifen can also be dissolved in corn oil (HY-Y1888) for use in inducing gene knockout in CreER transgenic mice. Tamoxifen has better solubility in corn oil compared to Tamoxifen Citrate (HY-13757).
For research use only. We do not sell to patients.
- Purity: 99.96%
- CAS No.: 10540-29-1
- Formula: C26H29NO
- Molecular Weight:371.51
-
Storage:
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
Publications Citing Use of MedChemExpress (MCE) Tamoxifen
More- Signal Transduct Target Ther. 2023 Feb 3;8(1):51. [Abstract]
- Science. 2026 Jul 2;393(6806):eaef0825. [Abstract]
- Science. 2026 Mar 19;391(6791):eadu7686. [Abstract]
- Cancer Cell. 2026 Feb 9;44(2):424-442.e14. [Abstract]
- Cancer Cell. 2024 Nov 11;42(11):1955-1969.e7. [Abstract]
- Cell. 2025 Sep 18;188(19):5194-5211.e16. [Abstract]
- Cell. 2025 May 29;188(11):3013-3029.e19. [Abstract]
- Cell. 2024 Sep 5;187(18):5064-5080.e14. [Abstract]
- Cell. 2022 Aug 4;185(16):3008-3024.e16. [Abstract]
- Immunity. 2024 Jan 9;57(1):106-123.e7. [Abstract]
- Immunity. 2022 Aug 9;55(8):1466-1482.e9. [Abstract]
- Immunity. 2020 Nov 17;53(5):1078-1094.e7. [Abstract]
- Cell Res. 2026 May 27. [Abstract]
- Cell Res. 2025 Feb;35(2):97-116. [Abstract]
- Gut. 2023 May;72(5):821-833. [Abstract]
- Cancer Commun (Lond). 2025 Oct 16. [Abstract]
- Cancer Commun (Lond). 2024 Nov;44(11):1350-1373. [Abstract]
- Sci Bull. 2025 Sep 29:S2095-9273(25)00984-3. [Abstract]
- Nat Neurosci. 2025 Jul;28(7):1404-1417. [Abstract]
- Cell Mol Immunol. 2026 May;23(5):471-490. [Abstract]
- Cell Mol Immunol. 2025 Oct 20. [Abstract]
- Cell Mol Immunol. 2025 Feb;22(2):134-149. [Abstract]
- Cell Mol Immunol. 2024 Oct;21(10):1131-1144. [Abstract]
- Nat Cell Biol. 2024 Dec;26(12):2099-2114. [Abstract]
- Cancer Res. 2024 Nov 15;84(22):3728-3742. [Abstract]
- Sci Immunol. 2025 Sep 5;10(111):eadq0457. [Abstract]
- Sci Immunol. 2025 Jul 11;10(109):eadu7962. [Abstract]
- Circ Res. 2025 Jan 17;136(2):e1-e19. [Abstract]
- Nat Commun. 2025 Apr 30;16(1):4047. [Abstract]
- Nat Commun. 2025 Jan 30;16(1):1175. [Abstract]
- Nat Commun. 2024 Dec 30;15(1):10838. [Abstract]
- Nat Commun. 2024 Nov 12;15(1):9770. [Abstract]
- Nat Commun. 2024 Sep 6;15(1):7791. [Abstract]
- Nat Commun. 2024 Oct 29;15(1):9337. [Abstract]
- Cell Death Differ. 2026 Jan 28. [Abstract]
- Cell Death Differ. 2025 Nov 26. [Abstract]
- Cell Death Differ. 2025 Jul 19. [Abstract]
- Neuron. 2026 Mar 16:S0896-6273(26)00137-6. [Abstract]
- Bone Res. 2024 Sep 6;12(1):53. [Abstract]
- Acta Pharm Sin B. 2026 May 12.
- Autophagy. 2026 May 31:1-22. [Abstract]
- Autophagy. 2025 Sep 29:1-19. [Abstract]
- Adv Sci (Weinh). 2026 May 20:e18564. [Abstract]
- Adv Sci (Weinh). 2026 Feb;13(10):e17825. [Abstract]
- Adv Sci (Weinh). 2025 Nov 10:e10991. [Abstract]
- Adv Sci (Weinh). 2025 Oct 14:e15374. [Abstract]
- Adv Sci (Weinh). 2025 Aug 4:e03972. [Abstract]
- Adv Sci (Weinh). 2025 Aug 11:e02535. [Abstract]
- Adv Sci (Weinh). 2024 Jun 5:e2401676. [Abstract]
- J Clin Invest. 2026 Apr 2;136(12):e196112. [Abstract]
- J Clin Invest. 2026 Mar 2;136(5):e196905. [Abstract]
- J Clin Invest. 2026 Jan 2;136(1):e195506. [Abstract]
- J Clin Invest. 2025 Oct 16:e188822. [Abstract]
- J Clin Invest. 2025 Jun 2;135(11):e184158. [Abstract]
- J Clin Invest. 2025 Jan 16;135(2):e178198. [Abstract]
- Cardiovasc Res. 2026 Mar 24:cvag069. [Abstract]
- Theranostics. 2026 Feb 4;16(8):4452-4470. [Abstract]
- Cardiovasc Res. 2025 Nov 11:cvaf219. [Abstract]
- Cardiovasc Res. 2025 Aug 7:cvaf136. [Abstract]
- Cardiovasc Res. 2025 May 6;121(4):568-584. [Abstract]
- Theranostics. 2024 Aug 1;14(11):4499-4518. [Abstract]
- Cardiovasc Res. 2024 Jun 4:cvae116. [Abstract]
- Theranostics. 2021 Sep 21;11(19):9623-9651. [Abstract]
- Theranostics. 2020 Aug 29;10(24):10874-10891. [Abstract]
- Theranostics. 2020 Sep 11;10(24):11159-11177. [Abstract]
- Chem Eng J. 2026 Mar 19.
- Nucleic Acids Res. 2022 Oct 14;50(18):10230-10248. [Abstract]
- J Adv Res. 2025 Jul 12:S2090-1232(25)00545-4. [Abstract]
- J Adv Res. 2024 Aug 3:S2090-1232(24)00323-0. [Abstract]
- J Adv Res. 2022 Nov:41:63-75. [Abstract]
- Biomaterials. 2024 Dec 27:317:123062. [Abstract]
- J Exp Clin Cancer Res. 2024 Jun 20;43(1):173. [Abstract]
- Sci Adv. 2026 Jun 12;12(24):eaed2731. [Abstract]
- Sci Adv. 2024 Jul 19;10(29):eadp5239. [Abstract]
- Sci Adv. 2024 Jul 5;10(27):eadm7373. [Abstract]
- Sci Adv. 2024 Feb 2;10(5):eadj7813. [Abstract]
- Sci Adv. 2023 Sep;9(35):eadg7125. [Abstract]
- Redox Biol. 2022 Nov:57:102509. [Abstract]
- Biomark Res. 2025 May 7;13(1):70. [Abstract]
- J Hazard Mater. 2023 Oct 15:460:132489. [Abstract]
- Research (Wash D C). 2025 Feb 19:8:0619. [Abstract]
- Cell Rep Med. 2025 Apr 2:102053. [Abstract]
- J Neuroinflammation. 2025 Dec 8. [Abstract]
- J Neuroinflammation. 2025 Oct 31;22(1):253. [Abstract]
- Mol Psychiatry. 2025 Aug 6. [Abstract]
- J Neuroinflammation. 2024 Nov 14;21(1):295. [Abstract]
- Cancer Lett. 2024 May 28:590:216839. [Abstract]
- Cancer Lett. 2024 Mar 1:584:216609. [Abstract]
- Int J Biol Sci. 2025 Mar 19;21(6):2462-2475. [Abstract]
- Cell Death Dis. 2026 Feb 9. [Abstract]
- Cell Death Dis. 2025 Nov 30. [Abstract]
- Cell Death Dis. 2025 Mar 25;16(1):201. [Abstract]
- Cell Death Dis. 2023 Dec 5;14(12):796. [Abstract]
- Cell Death Dis. 2021 Oct 26;12(11):1003. [Abstract]
- Sci China Life Sci. 2025 Jul;68(7):2010-2027. [Abstract]
- Proc Natl Acad Sci U S A. 2023 Jan 3;120(1):e2203779120. [Abstract]
- Proc Natl Acad Sci U S A. 2022 Oct 4;119(40):e2204716119. [Abstract]
- Proc Natl Acad Sci U S A. 2021 Apr 27;118(17):e2024258118. [Abstract]
- Cell Commun Signal. 2019 May 23;17(1):50. [Abstract]
- Dev Cell. 2025 Sep 3:S1534-5807(25)00530-1. [Abstract]
- Dev Cell. 2024 May 25:S1534-5807(24)00324-1. [Abstract]
- Phytomedicine. 2025 Dec 28:150:157748. [Abstract]
- Phytomedicine. 2024 May:127:155461. [Abstract]
- ACS Appl Mater Interfaces. 2025 Aug 27;17(34):48029-48043. [Abstract]
- Chemosphere. 2020 Jan;239:124705. [Abstract]
- Mater Des. 2025 Oct.
- Neoplasia. 2025 Feb 3:61:101125. [Abstract]
- Br J Pharmacol. 2024 Oct;181(20):3908-3925. [Abstract]
- NPJ Breast Cancer. 2025 Jul 17;11(1):73. [Abstract]
- Brain Behav Immun. 2024 Jan:115:705-717. [Abstract]
- NPJ Breast Cancer. 2022 Mar 10;8(1):31. [Abstract]
- Oncogene. 2025 Sep 16:10.1038/s41388-025-03571-1. [Abstract]
- Stem Cell Res Ther. 2025 Mar 5;16(1):111. [Abstract]
- Cell Rep. 2026 May 28;45(6):117471. [Abstract]
- Cell Rep. 2025 Dec 11;44(12):116678. [Abstract]
- Cell Rep. 2025 Nov 25;44(11):116563. [Abstract]
- Cell Rep. 2025 Aug 5;44(8):116112. [Abstract]
- Arch Toxicol. 2025 May 3. [Abstract]
- Cell Rep. 2025 Jan 2;44(1):115126. [Abstract]
- Cell Rep. 2024 May 10;43(5):114226. [Abstract]
- Cell Rep. 2024 Feb 17;43(2):113804. [Abstract]
- Cell Rep. 2024 Feb 15;43(2):113786. [Abstract]
- Cell Rep. 2023 Sep 30;42(10):113202. [Abstract]
- Cell Rep. 2023 Sep 19;42(10):113158. [Abstract]
- Br J Cancer. 2025 Dec 9. [Abstract]
- Br J Cancer. 2022 Sep;127(5):927-936. [Abstract]
- J Med Chem. 2020 Oct 8;63(19):11085-11099. [Abstract]
- Clin Transl Med. 2020 Jan;10(1):137-150. [Abstract]
- Transl Psychiatry. 2025 Aug 15;15(1):285. [Abstract]
- Cell Mol Life Sci. 2024 Jan 22;81(1):49. [Abstract]
- Cell Mol Life Sci. 2023 Mar 18;80(4):100. [Abstract]
- Cancer Cell Int. 2024 Dec 27;24(1):433. [Abstract]
- J Bone Miner Res. 2025 Mar 26:zjaf043. [Abstract]
- Front Immunol. 2024 Mar 27:15:1374943. [Abstract]
- Transl Res. 2023 Jul:257:54-65. [Abstract]
- Front Immunol. 2022 Mar 10;13:805420. [Abstract]
- Neurosci Bull. 2026 Mar 22. [Abstract]
- Neurosci Bull. 2025 May 2. [Abstract]
- Atherosclerosis. 2025 Dec:411:120558. [Abstract]
- J Invest Dermatol. 2023 Dec;143(12):2366-2377.e7. [Abstract]
- Biochem Pharmacol. 2026 Jun 12;251(Pt 2):118163. [Abstract]
- Biochem Pharmacol. 2026 May:247:117796. [Abstract]
- Cell Prolif. 2025 Dec 30:e70158. [Abstract]
- Biochem Pharmacol. 2025 Oct:240:117107. [Abstract]
- Cell Prolif. 2024 Jun 26:e13700. [Abstract]
- Biochem Pharmacol. 2024 May 9:225:116256. [Abstract]
- Breast Cancer Res. 2024 Mar 11;26(1):44. [Abstract]
- Cell Prolif. 2023 Jul;56(7):e13406. [Abstract]
- Biochem Pharmacol. 2021 Jun:188:114583. [Abstract]
- Cell Prolif. 2021 Jan;54(1):e12953. [Abstract]
- Pharmaceutics. 2022 Jan 12;14(1):176. [Abstract]
- J Ethnopharmacol. 2026 May 10:362:121345. [Abstract]
- Chem Biol Interact. 2024 Feb 1:389:110865. [Abstract]
- J Ethnopharmacol. 2024 Jan 10;318(Pt B):117075. [Abstract]
- Chem Biol Interact. 2022 Sep 25:365:110091. [Abstract]
- Biomacromolecules. 2015 Sep 14;16(9):2701-14. [Abstract]
- Cells. 2026 Feb 23;15(4):383. [Abstract]
- Glia. 2026 Jun;74(6):e70159. [Abstract]
- Life Sci. 2026 Mar 15:389:124236. [Abstract]
- Glia. 2025 Jul 28. [Abstract]
- Glia. 2024 Feb;72(2):396-410. [Abstract]
- J Clin Endocrinol Metab. 2021 Apr 23;106(5):1410-1426. [Abstract]
- CNS Neurosci Ther. 2026 Feb;32(2):e70756. [Abstract]
- PLoS Pathog. 2025 Sep 10;21(9):e1013464. [Abstract]
- Int J Mol Sci. 2025 Jul 9;26(14):6593. [Abstract]
- PLoS Pathog. 2025 Apr 10;21(4):e1013052. [Abstract]
- Int J Mol Sci. 2022 Feb 28;23(5):2664. [Abstract]
- Pharmaceuticals (Basel). 2026 May 19;19(5):795. [Abstract]
- Pharmaceuticals (Basel). 2026 Apr 24;19(5):667. [Abstract]
- Int Immunopharmacol. 2026 Jun 20:185:117023. [Abstract]
- Bioorg Chem. 2026 Jun 18:180:110129. [Abstract]
- Int Immunopharmacol. 2025 Sep 6:165:115494. [Abstract]
- Int Immunopharmacol. 2024 Oct 31;143(Pt 3):113485. [Abstract]
- mBio. 2023 Apr 25;14(2):e0054923. [Abstract]
- Neuropharmacology. 2026 Nov 1:298:111043. [Abstract]
- Cancers (Basel). 2023 Aug 11;15(16):4066. [Abstract]
- Cancers (Basel). 2021 Feb 3;13(4):599. [Abstract]
- Aquat Toxicol. 2026 Jun:295:107814. [Abstract]
- Exp Gerontol. 2026 Jan:213:112994. [Abstract]
- Exp Neurol. 2026 Sep:403:115819. [Abstract]
- J Cell Mol Med. 2024 Jan;28(1):e18007. [Abstract]
- J Cell Mol Med. 2020 Jan;24(2):1599-1613. [Abstract]
- iScience. 2025 Sep 10;28(10):113536. [Abstract]
- J Neurosci. 2024 Jun 19:e2192232024. [Abstract]
- Prog Neuropsychopharmacol Biol Psychiatry. 2026 Jun 20:147:111763. [Abstract]
- J Biol Chem. 2026 Jun;302(6):111480. [Abstract]
- Biomedicines. 2026 Jun 15;14(6):1344. [Abstract]
- JOR Spine. 2025 Nov 4;8(4):e70133. [Abstract]
- Sci Rep. 2025 Jul 1;15(1):22255. [Abstract]
- J Biol Chem. 2024 Dec 10:108070. [Abstract]
- Mol Cell Biochem. 2025 Apr;480(4):2423-2435. [Abstract]
- Cell Signal. 2024 May:117:111080. [Abstract]
- Neurobiol Stress. 2026 Mar 21:42:100804. [Abstract]
- Heliyon. 2024 Jun 14;10(12):e33104. [Abstract]
- Mol Med Rep. 2026 Jun;33(6):183. [Abstract]
- Med Oncol. 2025 Jul 21;42(8):358. [Abstract]
- Viruses. 2024 Apr 20;16(4):643. [Abstract]
- RNA Biol. 2020 Sep 20;1-13. [Abstract]
- Biotechnol J. 2026 May;21(5):e70236. [Abstract]
- Cardiovasc Drugs Ther. 2026 Mar 13. [Abstract]
- Naunyn Schmiedebergs Arch Pharmacol. 2025 May 28. [Abstract]
- Naunyn Schmiedebergs Arch Pharmacol. 2025 Mar 18. [Abstract]
- Cardiovasc Drugs Ther. 2024 Apr;38(2):237-252. [Abstract]
- J Pharm Biomed Anal. 2021 Feb 20:195:113870. [Abstract]
- Breast Cancer Res Treat. 2023 Dec;202(3):595-606. [Abstract]
- Bioorg Med Chem. 2023 Mar 15:82:117235. [Abstract]
- Oral Dis. 2025 Jul;31(7):2229-2242. [Abstract]
- Int J Biochem Cell Biol. 2024 May 9:172:106585. [Abstract]
- J Chromatogr B Analyt Technol Biomed Life Sci. 2024 Apr 15:1237:124100. [Abstract]
- Front Genet. 2022 Sep 20:13:992444. [Abstract]
- Appl Biol Chem. 2026 Jun 24;69(1):36.
- PLoS One. 2025 Jul 28;20(7):e0328698. [Abstract]
- Hear Res. 2026 Aug:478:109691. [Abstract]
- Chin J Integr Med. 2026 Jan 15. [Abstract]
- Pharmacol Biochem Behav. 2025 Dec:257:174114. [Abstract]
- J Steroid Biochem Mol Biol. 2024 Aug 13:106599. [Abstract]
- Biochem Biophys Res Commun. 2026 Aug 20:827:154022. [Abstract]
- Biochem Biophys Res Commun. 2025 Sep 1:777:152327. [Abstract]
- Oncol Lett. 2025 Feb 21;29(4):194. [Abstract]
- Biochem Biophys Res Commun. 2024 Oct 28:737:150916. [Abstract]
- Biochim Biophys Acta Gen Subj. 2023 Sep;1867(9):130413. [Abstract]
- Biochem Biophys Res Commun. 2020 Feb 19;522(4):862-868. [Abstract]
- Toxicol Res (Camb). 2022 Jul 22;11(4):673-682. [Abstract]
- Am J Transl Res. 2018 Jul 15;10(7):2184-2194. [Abstract]
- Cureus. 2025 Oct 20;17(10):e94996. [Abstract]
- Res Sq. 2026 Jun 2.
- bioRxiv. 2026 May 21.
- eGastroenterology. 2026 Mar 31;4(1):e100348. [Abstract]
- Res Sq. 2026 Feb 2.
- Res Sq. 2026 Feb 23.
- SSRN. 2025 Nov 6.
- SSRN. 2025 Sep 30.
- SSRN. 2025 Oct 13.
- bioRxiv. 2025 Oct 6.
- bioRxiv. 2025 Oct 14:2025.10.12.681919. [Abstract]
- bioRxiv. 2025 Oct 7:2025.10.06.680702. [Abstract]
- bioRxiv. 2025 Jun 17.
- bioRxiv. 2025 February 23.
- Res Sq. 2024 Oct 16.
- Res Sq. 2024 Aug 26.
- Patent. US20240217988A1.
- bioRxiv. 2024 August 04.
- Res Sq. 2024 Jun 04.
- SSRN. 2024 Mar 26.
- SSRN. 2024 Jan 10.
- Journal of the Institute of Science and Technology. 2023 Mar 3, 13(4), 2997-3006.
- bioRxiv. 2023 Dec 18.
- bioRxiv. 2023 Aug 22.
- Research Square Preprint. 2023 Aug 7.
- bioRxiv. 2023 Jun 22.
- bioRxiv. 2023 Mar 15:2023.03.14.532677. [Abstract]
- bioRxiv. 2023 Feb 7.
- bioRxiv. 2023 Jan 31.
- Universität Basel. 2022.
- Research Square Preprint. 2022 May.
- Research Square Preprint. 2022 May.
- Research Square Preprint. 2021 Oct.
- Res Sq. 2020 Dec 31:rs.3.rs-100914. [Abstract]
- bioRxiv. 2020 Mar.
-
In Vivo Efficacy Study
-
In Vivo Efficacy Study
-
Histological Imaging/Staining
-
IHC
-
WB
Biological Activity
|
Estrogen receptor |
HSP90 |
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| 518A2 | IC50 |
7.62 μM
Compound: 2
|
Cytotoxicity against human 518A2 cells after 96 hrs by SRB assay
Cytotoxicity against human 518A2 cells after 96 hrs by SRB assay
|
[PMID: 22749392] |
| 518A2 | IC50 |
7.62 μmol
Compound: 2
|
Cytotoxicity against human 518A2 cells after 96 hrs by SRB assay
Cytotoxicity against human 518A2 cells after 96 hrs by SRB assay
|
[PMID: 22749392] |
| A2058 | EC50 |
12.5 μM
Compound: TAM
|
Antiproliferative activity against human A2058 cells assessed as reduction in cell viability measured after 24 hrs by celltiter-blue assay
Antiproliferative activity against human A2058 cells assessed as reduction in cell viability measured after 24 hrs by celltiter-blue assay
|
[PMID: 31099568] |
| A253 cell line | IC50 |
8.92 μM
Compound: 2
|
Cytotoxicity against human A253 cells after 96 hrs by SRB assay
Cytotoxicity against human A253 cells after 96 hrs by SRB assay
|
[PMID: 22749392] |
| A253 cell line | IC50 |
8.92 μmol
Compound: 2
|
Cytotoxicity against human A253 cells after 96 hrs by SRB assay
Cytotoxicity against human A253 cells after 96 hrs by SRB assay
|
[PMID: 22749392] |
| A2780 | IC50 |
7.77 μM
Compound: 2
|
Cytotoxicity against human A2780 cells after 96 hrs by SRB assay
Cytotoxicity against human A2780 cells after 96 hrs by SRB assay
|
[PMID: 22749392] |
| A2780 | IC50 |
7.77 μmol
Compound: 2
|
Cytotoxicity against human A2780 cells after 96 hrs by SRB assay
Cytotoxicity against human A2780 cells after 96 hrs by SRB assay
|
[PMID: 22749392] |
| A2780 | GI50 |
30.3 μM
Compound: 1
|
Cytotoxicity against human A2780 cells assessed as cell growth inhibition after 72 hrs by MTS assay
Cytotoxicity against human A2780 cells assessed as cell growth inhibition after 72 hrs by MTS assay
|
[PMID: 27128175] |
| A-431 | ED50 |
7 μg/mL
Compound: TAM
|
Cytotoxicity against human A431 cells
Cytotoxicity against human A431 cells
|
[PMID: 16942038] |
| A-431 | IC50 |
>100 μM
Compound: Tamoxifen
|
Cytotoxicity against human A431 cells preincubated for 4 hrs followed by incubation in compound free media for 24 hrs by MTT assay
Cytotoxicity against human A431 cells preincubated for 4 hrs followed by incubation in compound free media for 24 hrs by MTT assay
|
[PMID: 29605808] |
| A549 | IC50 |
1.86 μg/mL
Compound: Tomoxifen
|
Cytotoxicity against human A549 cells by alamar blue assay
Cytotoxicity against human A549 cells by alamar blue assay
|
[PMID: 11720540] |
| A549 | IC50 |
9.66 μM
Compound: 2
|
Cytotoxicity against human A549 cells after 96 hrs by SRB assay
Cytotoxicity against human A549 cells after 96 hrs by SRB assay
|
[PMID: 22749392] |
| A549 | IC50 |
9.66 μmol
Compound: 2
|
Cytotoxicity against human A549 cells after 96 hrs by SRB assay
Cytotoxicity against human A549 cells after 96 hrs by SRB assay
|
[PMID: 22749392] |
| A549 | IC50 |
12 μM
Compound: TAM
|
Antiproliferative activity against human A549 cells after 48 hrs by MTT assay
Antiproliferative activity against human A549 cells after 48 hrs by MTT assay
|
[PMID: 23287057] |
| A549 | IC50 |
8.4 μM
Compound: Tamoxifen
|
Cytotoxicity against human A549 cells assessed as cell viability by MTT assay
Cytotoxicity against human A549 cells assessed as cell viability by MTT assay
|
[PMID: 26079090] |
| A549 | GI50 |
24.4 μM
Compound: Tamoxifen
|
Anti-proliferative activity against human A549 cells incubated for 48 hrs by SRB assay
Anti-proliferative activity against human A549 cells incubated for 48 hrs by SRB assay
|
[PMID: 26163220] |
| A549 | IC50 |
17.3 μM
Compound: Tamoxifen
|
Anticancer activity against human A549 cells measured after 48 hrs by SRB assay
Anticancer activity against human A549 cells measured after 48 hrs by SRB assay
|
[PMID: 27671497] |
| A549 | IC50 |
17.3 μM
Compound: Tamoxifen
|
Cytotoxicity against human A549 cells preincubated for 4 hrs followed by incubation in compound free media for 24 hrs by MTT assay
Cytotoxicity against human A549 cells preincubated for 4 hrs followed by incubation in compound free media for 24 hrs by MTT assay
|
[PMID: 29605808] |
| A549 | IC50 |
10.87 μM
Compound: Tamoxifen
|
Antiproliferative activity against human A549 cells by MTT assay
Antiproliferative activity against human A549 cells by MTT assay
|
[PMID: 31546197] |
| A549 | IC50 |
10.08 μM
Compound: Tamoxifen
|
Antiproliferative activity against human A549 cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay
Antiproliferative activity against human A549 cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay
|
[PMID: 31884407] |
| Astrocyte | IC50 |
>10 μM
Compound: Tamoxifen
|
Cytotoxicity against normal human astrocytes assessed as cell viability incubated for 72 hrs by WST-1 method
Cytotoxicity against normal human astrocytes assessed as cell viability incubated for 72 hrs by WST-1 method
|
[PMID: 26355532] |
| B16-F10 | IC50 |
64.87 μM
Compound: Tam
|
Antiproliferative activity mouse B16F10 cells after 2 days by MTT assay
Antiproliferative activity mouse B16F10 cells after 2 days by MTT assay
|
[PMID: 25222876] |
| Caco-2 | IC50 |
29 μM
Compound: Tamoxifen
|
TP_TRANSPORTER: transepithelial transport of Rhodamine 123 (basal to apical) in Caco-2 cells
TP_TRANSPORTER: transepithelial transport of Rhodamine 123 (basal to apical) in Caco-2 cells
|
[PMID: 15386482] |
| Caco-2 | EC50 |
56.5 μM
Compound: Tamoxifen
|
Inhibition of P-glycoprotein-mediated [3H]vinblastine transport in human Caco-2 cells
Inhibition of P-glycoprotein-mediated [3H]vinblastine transport in human Caco-2 cells
|
[PMID: 18524592] |
| Cancer cell lines | IC50 |
10.6 μM
Compound: Tamoxifen
|
Antiproliferative activity in MDA-MB 231 human breast cancer cells
Antiproliferative activity in MDA-MB 231 human breast cancer cells
|
[PMID: 15658875] |
| CHO | IC50 |
>100 μM
Compound: Tam
|
Antiproliferative activity against CHO cells after 2 days by MTT assay
Antiproliferative activity against CHO cells after 2 days by MTT assay
|
[PMID: 25222876] |
| DLD-1 | IC50 |
4.78 μM
Compound: 2
|
Cytotoxicity against human DLD1 cells after 96 hrs by SRB assay
Cytotoxicity against human DLD1 cells after 96 hrs by SRB assay
|
[PMID: 22749392] |
| DLD-1 | IC50 |
4.78 μmol
Compound: 2
|
Cytotoxicity against human DLD1 cells after 96 hrs by SRB assay
Cytotoxicity against human DLD1 cells after 96 hrs by SRB assay
|
[PMID: 22749392] |
| DLD-1 | IC50 |
11.06 μM
Compound: Tamoxifen
|
Anticancer activity against human DLD1 cells measured after 48 hrs by SRB assay
Anticancer activity against human DLD1 cells measured after 48 hrs by SRB assay
|
[PMID: 27671497] |
| DLD-1 | IC50 |
16.3 μM
Compound: Tamoxifen
|
Cytotoxicity against human DLD1 cells preincubated for 4 hrs followed by incubation in compound free media for 24 hrs by MTT assay
Cytotoxicity against human DLD1 cells preincubated for 4 hrs followed by incubation in compound free media for 24 hrs by MTT assay
|
[PMID: 29605808] |
| DU-145 | GI50 |
6.07 μM
Compound: Tamoxifen
|
Anticancer activity against human DU145 cells after 24 hrs by SRB assay
Anticancer activity against human DU145 cells after 24 hrs by SRB assay
|
[PMID: 19733085] |
| DU-145 | IC50 |
5.5 μM
Compound: TAM
|
Antiproliferative activity against human DU145 cells after 48 hrs by MTT assay
Antiproliferative activity against human DU145 cells after 48 hrs by MTT assay
|
[PMID: 23287057] |
| DU-145 | IC50 |
28.9 μM
Compound: Tamoxifen
|
Cytotoxicity against ERalpha-deficient human DU145 cells expressing ERbeta assessed as growth inhibition after 72 hrs by MTT assay
Cytotoxicity against ERalpha-deficient human DU145 cells expressing ERbeta assessed as growth inhibition after 72 hrs by MTT assay
|
[PMID: 23786452] |
| DU-145 | GI50 |
19.3 μM
Compound: Tamoxifen
|
Anti-proliferative activity against human DU145 cells incubated for 48 hrs by SRB assay
Anti-proliferative activity against human DU145 cells incubated for 48 hrs by SRB assay
|
[PMID: 26163220] |
| DU-145 | IC50 |
18.07 μM
Compound: Tamoxifen
|
Anticancer activity against human DU145 cells measured after 48 hrs by SRB assay
Anticancer activity against human DU145 cells measured after 48 hrs by SRB assay
|
[PMID: 27671497] |
| DU-145 | IC50 |
10.87 μM
Compound: Tamoxifen
|
Antiproliferative activity against human DU145 cells by MTT assay
Antiproliferative activity against human DU145 cells by MTT assay
|
[PMID: 31546197] |
| EKVX | GI50 |
6.3 μM
Compound: TAM
|
Cytotoxicity against human EKVX cells assessed as growth inhibition after 48 hrs by SRB assay
Cytotoxicity against human EKVX cells assessed as growth inhibition after 48 hrs by SRB assay
|
[PMID: 26896706] |
| EL4 | IC50 |
535 nM
Compound: 1a
|
Inhibition of [3H]thymidine incorporation into EL4 cell proliferation
Inhibition of [3H]thymidine incorporation into EL4 cell proliferation
|
[PMID: 1573630] |
| FaDu | IC50 |
5.39 μM
Compound: Tamoxifen
|
Anticancer activity against human FADU cells measured after 48 hrs by SRB assay
Anticancer activity against human FADU cells measured after 48 hrs by SRB assay
|
[PMID: 27671497] |
| Fibroblast | IC50 |
>20 μM
Compound: TAM
|
Antiproliferative activity against mouse fibroblasts after 48 hrs by MTT assay
Antiproliferative activity against mouse fibroblasts after 48 hrs by MTT assay
|
[PMID: 23287057] |
| Fibroblast | CC50 |
11.1 μM
Compound: Tamoxifen
|
Cytotoxicity against human HSF cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
Cytotoxicity against human HSF cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
|
[PMID: 33373820] |
| Fibroblast | CC50 |
12.7 μM
Compound: Tamoxifen
|
Cytotoxicity against human HSF cells assessed as reduction in colony formation incubated for 7 days by crystal violet staining based assay
Cytotoxicity against human HSF cells assessed as reduction in colony formation incubated for 7 days by crystal violet staining based assay
|
[PMID: 33373820] |
| HCT-116 | IC50 |
45 μM
Compound: Tamoxifen
|
Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay
Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay
|
[PMID: 31884407] |
| HCT-15 | GI50 |
3.16 μM
Compound: TAM
|
Cytotoxicity against human HCT15 cells assessed as growth inhibition after 48 hrs by SRB assay
Cytotoxicity against human HCT15 cells assessed as growth inhibition after 48 hrs by SRB assay
|
[PMID: 26896706] |
| HEK293 | IC50 |
10 μM
Compound: Tamoxifen
|
Cytotoxicity against HEK293 cells after 24 hrs by MTT assay
Cytotoxicity against HEK293 cells after 24 hrs by MTT assay
|
[PMID: 20605470] |
| HEK293 | IC50 |
10 μM
Compound: Tamoxifen
|
Antiproliferative activity against human HEK293 cells after 48 hrs by MTT assay
Antiproliferative activity against human HEK293 cells after 48 hrs by MTT assay
|
[PMID: 21871812] |
| HEK293 | IC50 |
26 μM
Compound: TAM
|
Cytotoxicity against human HEK293 cells after 24 hrs by MTT assay
Cytotoxicity against human HEK293 cells after 24 hrs by MTT assay
|
[PMID: 24457094] |
| HEK293 | IC50 |
50 μM
Compound: Tamoxifen
|
Cytotoxicity against human HEK293 cells after 24 hrs by MTT assay
Cytotoxicity against human HEK293 cells after 24 hrs by MTT assay
|
[PMID: 24880230] |
| HEK293 | CC50 |
62 μM
Compound: Tamoxifen
|
Cytotoxicity against HEK293 cells assessed as reduction in cell viability incubated for 24 hrs by resazurin based assay
Cytotoxicity against HEK293 cells assessed as reduction in cell viability incubated for 24 hrs by resazurin based assay
|
[PMID: 28257200] |
| HEK293 | IC50 |
20.93 μM
Compound: Tamoxifen
|
Antiproliferative activity against HEK293 cells after 48 hrs by MTT assay
Antiproliferative activity against HEK293 cells after 48 hrs by MTT assay
|
[PMID: 29054359] |
| HEK293 | CC50 |
13 μg/mL
Compound: TAM
|
Cytotoxicity against HEK293 cells after 24 hrs by resazurin dye-based fluorescence analysis
Cytotoxicity against HEK293 cells after 24 hrs by resazurin dye-based fluorescence analysis
|
[PMID: 30316060] |
| HEK293 | CC50 |
39.4 μM
Compound: Tamoxifen
|
Cytotoxicity against HEK293 cells after 24 hrs by resazurin dye-based fluorescence analysis
Cytotoxicity against HEK293 cells after 24 hrs by resazurin dye-based fluorescence analysis
|
[PMID: 30322754] |
| HEK293 | CC50 |
13.1 μg/mL
Compound: Tamoxifen
|
Cytotoxicity against human HEK293 cells assessed as reduction in cell growth incubated for 20 hrs by resazurin dye-based fluorometric assay
Cytotoxicity against human HEK293 cells assessed as reduction in cell growth incubated for 20 hrs by resazurin dye-based fluorometric assay
|
[PMID: 30831407] |
| HEK293 | CC50 |
13.1 μg/mL
Compound: Tamoxifen
|
Cytotoxicity against HEK293 cells assessed as decrease in cell viability after 20 hrs by resazurin dye-based fluorescence assay
Cytotoxicity against HEK293 cells assessed as decrease in cell viability after 20 hrs by resazurin dye-based fluorescence assay
|
[PMID: 30901686] |
| HEK293 | IC50 |
24 μM
Compound: Tamoxifen
|
Cytotoxicity against HEK293 cells measured after 20 hrs by resazurin dye based fluorescence assay
Cytotoxicity against HEK293 cells measured after 20 hrs by resazurin dye based fluorescence assay
|
[PMID: 30975502] |
| HEK293 | IC50 |
>50 μM
Compound: Tamoxifen
|
Cytotoxicity against HEK293 cells by MTT assay
Cytotoxicity against HEK293 cells by MTT assay
|
[PMID: 31546197] |
| HEK293 | CC50 |
9 μg/mL
Compound: Tamoxifen
|
Cytotoxicity against HEK293 cells measured after 20 hrs by resazurin dye based fluorescence assay
Cytotoxicity against HEK293 cells measured after 20 hrs by resazurin dye based fluorescence assay
|
[PMID: 32619924] |
| HEK293 | CC50 |
9 μg/mL
Compound: Tamoxifen
|
Cytotoxicity against HEK293 cells assessed as cell viability after 20 hrs by fluorescence assay
Cytotoxicity against HEK293 cells assessed as cell viability after 20 hrs by fluorescence assay
|
[PMID: 33609657] |
| HEK293 | CC50 |
9 μg/mL
Compound: Tamoxifen
|
Cytotoxicity against human HEK-293 cells incubated for 23 hrs by CO-ADD method
Cytotoxicity against human HEK-293 cells incubated for 23 hrs by CO-ADD method
|
[PMID: 33738069] |
| HEK293 | IC50 |
22.4 μM
Compound: TAM
|
Cytotoxicity against human HEK293 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
Cytotoxicity against human HEK293 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
|
[PMID: 34153643] |
| HEK293 | IC50 |
26.33 μM
Compound: 1
|
Cytotoxicity against human HEK293 cells assessed as cell viability after 24 hrs by MTT assay
Cytotoxicity against human HEK293 cells assessed as cell viability after 24 hrs by MTT assay
|
[PMID: 35276362] |
| HEK293 | IC50 |
24 μM
Compound: Tamoxifen
|
Cytotoxicity against HEK293 cells assessed as cell growth inhibition measured after 20 hrs by resazurin dye based assay
Cytotoxicity against HEK293 cells assessed as cell growth inhibition measured after 20 hrs by resazurin dye based assay
|
[PMID: 35477062] |
| HEK-293T | IC50 |
0.039 μM
Compound: Tamoxifen
|
Antagonist activity at Gal4 DBD-fused human ERalpha LBD expressed in HEK293T cells assessed as inhibition of estradiol-induced transcriptional activation after 20 hrs by luciferase reporter gene assay
Antagonist activity at Gal4 DBD-fused human ERalpha LBD expressed in HEK293T cells assessed as inhibition of estradiol-induced transcriptional activation after 20 hrs by luciferase reporter gene assay
|
[PMID: 23786452] |
| HeLa | IC50 |
622 nM
Compound: 6
|
Inhibition of 17-beta-estradiol mediated luciferase transcription in HeLa cells expressing human estrogen receptor alpha; ERE assay
Inhibition of 17-beta-estradiol mediated luciferase transcription in HeLa cells expressing human estrogen receptor alpha; ERE assay
|
[PMID: 15658851] |
| HeLa | IC50 |
>1000 nM
Compound: 6
|
Inhibition of 17-beta-estradiol mediated luciferase transcription in HeLa cells expressing human estrogen receptor beta; ERE assay
Inhibition of 17-beta-estradiol mediated luciferase transcription in HeLa cells expressing human estrogen receptor beta; ERE assay
|
[PMID: 15658851] |
| HeLa | IC50 |
12.5 μM
Compound: Tamoxifen
|
Cytotoxicity against human HeLa cells after 24 hrs by MTT assay
Cytotoxicity against human HeLa cells after 24 hrs by MTT assay
|
[PMID: 20605470] |
| HeLa | GI50 |
32.6 μM
Compound: 1
|
Antiproliferative activity against human HeLa cells after 72 hrs by trypan blue assay
Antiproliferative activity against human HeLa cells after 72 hrs by trypan blue assay
|
[PMID: 23735829] |
| HeLa | GI50 |
12 μM
Compound: 1
|
Cytotoxicity against human HeLa cells assessed as cell growth inhibition after 72 hrs by trypan blue assay
Cytotoxicity against human HeLa cells assessed as cell growth inhibition after 72 hrs by trypan blue assay
|
[PMID: 27128175] |
| HeLa | IC50 |
8.85 μM
Compound: Tamoxifen
|
Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 24 hrs by MTT assay
Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 24 hrs by MTT assay
|
[PMID: 28838694] |
| HeLa | IC50 |
0.341 μM
Compound: Tamoxifen
|
Antagonist activity at full length ERalpha (unknown origin) expressed in human HeLa cells incubated for 24 hrs by ERE-driven luciferase reporter gene assay
Antagonist activity at full length ERalpha (unknown origin) expressed in human HeLa cells incubated for 24 hrs by ERE-driven luciferase reporter gene assay
|
[PMID: 28882502] |
| HeLa | IC50 |
1.53 μM
Compound: Tamoxifen
|
Antagonist activity at full length ERbeta (unknown origin) expressed in human HeLa cells incubated for 24 hrs by ERE-driven luciferase reporter gene assay
Antagonist activity at full length ERbeta (unknown origin) expressed in human HeLa cells incubated for 24 hrs by ERE-driven luciferase reporter gene assay
|
[PMID: 28882502] |
| HeLa | IC50 |
0.73 μM
Compound: Tamoxifen
|
Inhibition of Ebolavirus glycoprotein/matrix protein VP40 entry in human HeLa cells after 4.5 hrs beta-lactamase reporter assay
Inhibition of Ebolavirus glycoprotein/matrix protein VP40 entry in human HeLa cells after 4.5 hrs beta-lactamase reporter assay
|
[PMID: 29624387] |
| HeLa | IC50 |
10.87 μM
Compound: Tamoxifen
|
Antiproliferative activity against human HeLa cells by MTT assay
Antiproliferative activity against human HeLa cells by MTT assay
|
[PMID: 31546197] |
| Hepatocyte | EC50 |
34.4 μM
Compound: Tamoxifen
|
Cytotoxicity against human hepatocytes assessed as reduction in cell viability after 24 hrs by ATP detection based assay
Cytotoxicity against human hepatocytes assessed as reduction in cell viability after 24 hrs by ATP detection based assay
|
[PMID: 22531045] |
| Hepatocyte | EC50 |
67.6 μM
Compound: Tamoxifen
|
Cytotoxicity against human hepatocytes assessed as reduction in cell viability after 4 hrs by LDH release assay
Cytotoxicity against human hepatocytes assessed as reduction in cell viability after 4 hrs by LDH release assay
|
[PMID: 22531045] |
| Hepatocyte | EC50 |
71.4 μM
Compound: Tamoxifen
|
Cytotoxicity against human hepatocytes assessed as reduction in cell viability after 4 hrs by ATP detection based assay
Cytotoxicity against human hepatocytes assessed as reduction in cell viability after 4 hrs by ATP detection based assay
|
[PMID: 22531045] |
| HepG2 | IC50 |
23.4 μM
Compound: tamoxifen
|
Cytotoxicity against human HepG2 cells after 24 hrs by CellTiter-BlueCell viability assay
Cytotoxicity against human HepG2 cells after 24 hrs by CellTiter-BlueCell viability assay
|
[PMID: 20545334] |
| HepG2 | IC50 |
6.3 μM
Compound: TAM
|
Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay
Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay
|
[PMID: 23287057] |
| HepG2 | GI50 |
21.7 μM
Compound: Tamoxifen
|
Anti-proliferative activity against human HepG2 cells incubated for 48 hrs by SRB assay
Anti-proliferative activity against human HepG2 cells incubated for 48 hrs by SRB assay
|
[PMID: 26163220] |
| HepG2 | EC50 |
35 μM
Compound: Tamoxifen
|
Cytotoxicity in human HepG2 cells assessed as induction of cell necrosis incubated for 4 hrs by LDH release assay
Cytotoxicity in human HepG2 cells assessed as induction of cell necrosis incubated for 4 hrs by LDH release assay
|
[PMID: 27652492] |
| HepG2 | EC50 |
35 μM
Compound: Tamoxifen
|
Cytotoxicity in human HepG2 cells assessed as reduction in cell viability incubated for 4 hrs by CellTiter-Glo assay
Cytotoxicity in human HepG2 cells assessed as reduction in cell viability incubated for 4 hrs by CellTiter-Glo assay
|
[PMID: 27652492] |
| HepG2 | CC50 |
62 μM
Compound: Tamoxifen
|
Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 24 hrs by resazurin based assay
Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 24 hrs by resazurin based assay
|
[PMID: 28257200] |
| HepG2 | CC50 |
24.7 μM
Compound: Tamoxifen
|
Cytotoxicity against human HepG2 cells after 24 hrs by resazurin dye-based fluorescence analysis
Cytotoxicity against human HepG2 cells after 24 hrs by resazurin dye-based fluorescence analysis
|
[PMID: 30322754] |
| HepG2 | IC50 |
12 μM
Compound: Tamoxifen
|
Cytotoxicity against human HepG2 cells after 24 hrs by MTT assay
Cytotoxicity against human HepG2 cells after 24 hrs by MTT assay
|
[PMID: 30613327] |
| HepG2 | IC50 |
23.4 μM
Compound: Tamoxifen
|
Cytotoxicity against human HepG2 cells
Cytotoxicity against human HepG2 cells
|
[PMID: 32386856] |
| HepG2 | IC50 |
19.6 μM
Compound: Tamoxifen
|
Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 24 hrs by cell-titer 96 aqueous one solution cell proliferation assay
Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 24 hrs by cell-titer 96 aqueous one solution cell proliferation assay
|
[PMID: 34015704] |
| HepG2 | IC50 |
11.7 μM
Compound: Tamoxifen
|
Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 24 hrs in DMEM/10% FBS supplemented with galactose by CellTiter-Glo luminescent assay
Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 24 hrs in DMEM/10% FBS supplemented with galactose by CellTiter-Glo luminescent assay
|
[PMID: 37736177] |
| HepG2 | IC50 |
23.4 μM
Compound: Tamoxifen
|
Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 24 hrs in DMEM/10% FBS supplemented with glucose by CellTiter-Glo luminescent assay
Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 24 hrs in DMEM/10% FBS supplemented with glucose by CellTiter-Glo luminescent assay
|
[PMID: 37736177] |
| HepG2 | CC50 |
6.15 μg/mL
Compound: Tamoxifen
|
Cytotoxicity against human HepG2 cells assessed as reduction in cell viability by MTT assay
Cytotoxicity against human HepG2 cells assessed as reduction in cell viability by MTT assay
|
[PMID: 38784457] |
| HepG2 | IC50 |
11.72 μM
Compound: Tamoxifen
|
Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 24 hrs by Cell Titer Glo assay
Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 24 hrs by Cell Titer Glo assay
|
[PMID: 39026652] |
| HL-60 | IC50 |
5.9 μg/mL
Compound: 1, Tamoxifen
|
Growth inhibition of human HL60 cells after 4 hrs by MTT assay
Growth inhibition of human HL60 cells after 4 hrs by MTT assay
|
[PMID: 17904372] |
| HL-60 | IC50 |
14.3 μM
Compound: Tamoxifen
|
Cytotoxicity against human HL60 cells after 72 hrs by WST1 assay in presence of 20% FBS
Cytotoxicity against human HL60 cells after 72 hrs by WST1 assay in presence of 20% FBS
|
[PMID: 22901895] |
| Hs-578T | ED50 |
7 μg/mL
Compound: TAM
|
Cytotoxicity against human HS 587-T cells lacking ER
Cytotoxicity against human HS 587-T cells lacking ER
|
[PMID: 16942038] |
| HT-29 | IC50 |
1.86 μg/mL
Compound: Tomoxifen
|
Cytotoxicity against human HT-29 cells by alamar blue assay
Cytotoxicity against human HT-29 cells by alamar blue assay
|
[PMID: 11720540] |
| HT-29 | IC50 |
38.6 μM
Compound: tamoxifen
|
Cytotoxicity against human HT-29 cells after 24 hrs by CellTiter-BlueCell viability assay
Cytotoxicity against human HT-29 cells after 24 hrs by CellTiter-BlueCell viability assay
|
[PMID: 20545334] |
| HT-29 | GI50 |
9.5 μM
Compound: Tamoxifen
|
Growth inhibition of human HT-29 cells
Growth inhibition of human HT-29 cells
|
[PMID: 23403084] |
| Ishikawa | IC50 |
170 nM
Compound: 1a
|
Antiestrogenic activity in human Ishikawa cells assessed as inhibition of estrogen-induced alkaline phosphatase activity after 72 hrs
Antiestrogenic activity in human Ishikawa cells assessed as inhibition of estrogen-induced alkaline phosphatase activity after 72 hrs
|
[PMID: 18835176] |
| Ishikawa | IC50 |
22.5 μM
Compound: Tamoxifen
|
Antiproliferative activity against human Ishikawa cells expressing estrogen receptor after 48 hrs by MTT assay
Antiproliferative activity against human Ishikawa cells expressing estrogen receptor after 48 hrs by MTT assay
|
[PMID: 21871812] |
| Ishikawa | IC50 |
6 μM
Compound: Tamoxifen
|
Antiproliferative activity against human Ishikawa cells incubated for 48 hrs by MTT assay
Antiproliferative activity against human Ishikawa cells incubated for 48 hrs by MTT assay
|
[PMID: 27176944] |
| Ishikawa | IC50 |
7.87 μg/mL
Compound: Tamoxifen
|
Inhibition of estradiol-induced proliferation in human Ishikawa cells after 72 hrs by Cell-titer-Glo assay
Inhibition of estradiol-induced proliferation in human Ishikawa cells after 72 hrs by Cell-titer-Glo assay
|
[PMID: 28442256] |
| Ishikawa | IC50 |
16.47 μM
Compound: Tamoxifen
|
Antiproliferative activity against human Ishikawa cells after 48 hrs by MTT assay
Antiproliferative activity against human Ishikawa cells after 48 hrs by MTT assay
|
[PMID: 28460819] |
| Ishikawa | IC50 |
20.65 μM
Compound: Tamoxifen
|
Cytotoxicity in human Ishikawa cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
Cytotoxicity in human Ishikawa cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
|
[PMID: 28942113] |
| Ishikawa | IC50 |
26.52 μM
Compound: Tamoxifen
|
Antiproliferative activity against human Ishikawa cells after 48 hrs by MTT assay
Antiproliferative activity against human Ishikawa cells after 48 hrs by MTT assay
|
[PMID: 29587221] |
| Ishikawa | IC50 |
16.78 μM
Compound: Tamoxifen
|
Antiproliferative activity against human Ishikawa cells assessed as reduction in cell growth incubated for 48 hrs by CCK8 assay
Antiproliferative activity against human Ishikawa cells assessed as reduction in cell growth incubated for 48 hrs by CCK8 assay
|
[PMID: 34022716] |
| Ishikawa | IC50 |
14.58 μM
Compound: Tamoxifen
|
Antiproliferative activity against ER-positive human Ishikawa cells assessed as inhibition of cell growth incubated for 48 hrs by CCK8 assay
Antiproliferative activity against ER-positive human Ishikawa cells assessed as inhibition of cell growth incubated for 48 hrs by CCK8 assay
|
[PMID: 34509864] |
| Ishikawa | EC50 |
33 nM
Compound: 2
|
Concentration of compound required to induce 50 % of the maximum stimulation of alkaline phosphatase activity in Ishikawa cells
Concentration of compound required to induce 50 % of the maximum stimulation of alkaline phosphatase activity in Ishikawa cells
|
[PMID: 8201587] |
| Ishikawa | IC50 |
0.42 μM
Compound: tamoxifen
|
Antiestrogenic activity in human Ishikawa cells assessed as inhibition of estrogen-induced alkaline phosphatase activity after 4 days by ELISA
Antiestrogenic activity in human Ishikawa cells assessed as inhibition of estrogen-induced alkaline phosphatase activity after 4 days by ELISA
|
[PMID: 9784163] |
| J774.A1 | CC50 |
11.06 μM
Compound: Tamoxifen
|
Cytotoxicity against mouse J774A.1 cells assessed as reduction in cell viability incubated for 24 hrs by neutral red uptake assay
Cytotoxicity against mouse J774A.1 cells assessed as reduction in cell viability incubated for 24 hrs by neutral red uptake assay
|
[PMID: 31376569] |
| Jurkat | IC50 |
8.3 μM
Compound: Tamoxifen
|
Cytotoxicity against human Jurkat cells after 48 hrs by MTT assay
Cytotoxicity against human Jurkat cells after 48 hrs by MTT assay
|
[PMID: 23792352] |
| K562 | GI50 |
5.2 μM
Compound: tamoxifen
|
Antiproliferative activity against human K562 cells after 72 hrs
Antiproliferative activity against human K562 cells after 72 hrs
|
[PMID: 25420175] |
| KB | ED50 |
9 μg/mL
Compound: TAM
|
Cytotoxicity against human KB cells
Cytotoxicity against human KB cells
|
[PMID: 16942038] |
| L6 | IC50 |
4.9 μg/mL
Compound: tamoxifen
|
Cytotoxicity against rat L6 cells
Cytotoxicity against rat L6 cells
|
[PMID: 19168363] |
| Leukemia cell | GI50 |
2.08 μM
Compound: TAM
|
Antiproliferative activity against human leukemia cells
Antiproliferative activity against human leukemia cells
|
[PMID: 32898794] |
| M21 | GI50 |
11 μM
Compound: Tamoxifen
|
Growth inhibition of human M21 cells
Growth inhibition of human M21 cells
|
[PMID: 23403084] |
| MCF-10A | IC50 |
>50 μM
Compound: Tamoxifen
|
Cytotoxicity against human MCF-10A cells after 48 hrs by MTT assay
Cytotoxicity against human MCF-10A cells after 48 hrs by MTT assay
|
[PMID: 33340662] |
| MCF-10A | IC50 |
>1000 μM
Compound: Tamoxifen
|
Cytotoxicity against human MCF-10A cells assessed as inhibition of cell growth incubated for 72 hrs by Hoechst 33342/propidium iodide staining based fluorescence analysis
Cytotoxicity against human MCF-10A cells assessed as inhibition of cell growth incubated for 72 hrs by Hoechst 33342/propidium iodide staining based fluorescence analysis
|
[PMID: 36603398] |
| MCF-10A | IC50 |
>1000 μM
Compound: Tamoxifen
|
Cytotoxicity against human MCF-10A cells assessed as inhibition of cell growth incubated for 24 hrs by Hoechst 33342/propidium iodide staining based fluorescence analysis
Cytotoxicity against human MCF-10A cells assessed as inhibition of cell growth incubated for 24 hrs by Hoechst 33342/propidium iodide staining based fluorescence analysis
|
[PMID: 36603398] |
| MCF-10A | IC50 |
14.267 μM
Compound: 1; TMX
|
Anticancer activity against human MCF-10A cells assessed as inhibition of cell growth incubated for 24 hrs by CVDK-8 method
Anticancer activity against human MCF-10A cells assessed as inhibition of cell growth incubated for 24 hrs by CVDK-8 method
|
[PMID: 37484572] |
| MCF-10A | IC50 |
15 μM
Compound: 1; TMX
|
Antiproliferative activity against human MCF-10A cells assessed as inhibition of cell growth
Antiproliferative activity against human MCF-10A cells assessed as inhibition of cell growth
|
[PMID: 37484572] |
| MCF-10A | IC50 |
8.263 μM
Compound: 1; TMX
|
Anticancer activity against human MCF-10A cells assessed as inhibition of cell growth incubated for 48 hrs by CVDK-8 method
Anticancer activity against human MCF-10A cells assessed as inhibition of cell growth incubated for 48 hrs by CVDK-8 method
|
[PMID: 37484572] |
| MCF-10A | IC50 |
26.8 μM
Compound: TMX
|
Cytotoxicity against human MCF-10A assessed as reduction in cell viability measured after 48 hrs by WST-1 assay
Cytotoxicity against human MCF-10A assessed as reduction in cell viability measured after 48 hrs by WST-1 assay
|
[PMID: 38020071] |
| MCF7 | IC50 |
11.28 μM
Compound: 1a
|
Antiproliferative activity against Human MCF-7 Breast cancer cell line in vitro.
Antiproliferative activity against Human MCF-7 Breast cancer cell line in vitro.
|
[PMID: 11297454] |
| MCF7 | IC50 |
11 μM
Compound: Tamoxifen
|
Inhibitory concentration against MCF-7 (ER+) cell line using SRB assay
Inhibitory concentration against MCF-7 (ER+) cell line using SRB assay
|
[PMID: 12565971] |
| MCF7 | EC50 |
10 nM
Compound: 3 (Tamoxifen)
|
Effective concentration against MCF-7 breast tumor cells using MCF-7 assay.
Effective concentration against MCF-7 breast tumor cells using MCF-7 assay.
|
[PMID: 12825935] |
| MCF7 | IC50 |
580 nM
Compound: 3 (Tamoxifen)
|
Inhibitory concentration against MCF-7 breast tumor cells using MCF-7 assay.
Inhibitory concentration against MCF-7 breast tumor cells using MCF-7 assay.
|
[PMID: 12825935] |
| MCF7 | IC50 |
70 nM
Compound: Tamoxifen
|
Inhibition of estrogen receptor positive MCF-7 breast cancer cell proliferation
Inhibition of estrogen receptor positive MCF-7 breast cancer cell proliferation
|
[PMID: 14971899] |
| MCF7 | IC50 |
2.3 μM
Compound: Tamoxifen
|
Antiproliferative activity in MCF-7 human breast cancer cells
Antiproliferative activity in MCF-7 human breast cancer cells
|
[PMID: 15658875] |
| MCF7 | ED50 |
5 μg/mL
Compound: TAM
|
Cytotoxicity against human MCF7 cells expressing ER
Cytotoxicity against human MCF7 cells expressing ER
|
[PMID: 16942038] |
| MCF7 | IC50 |
5.09 μM
Compound: TAM
|
Antiproliferative activity against MCF7 cells at 3 mg/kg/day after 48 hrs
Antiproliferative activity against MCF7 cells at 3 mg/kg/day after 48 hrs
|
[PMID: 16979337] |
| MCF7 | IC50 |
580 nM
Compound: tamoxifen
|
Antiproliferative activity against human MCF7 cells after 24 hrs by MTS assay
Antiproliferative activity against human MCF7 cells after 24 hrs by MTS assay
|
[PMID: 18272256] |
| MCF7 | IC50 |
4.12 μM
Compound: 1a
|
Antiproliferative activity against estrogen receptor dependent human MCF7 cells after 72 hrs by MTT assay
Antiproliferative activity against estrogen receptor dependent human MCF7 cells after 72 hrs by MTT assay
|
[PMID: 18835176] |
| MCF7 | IC50 |
10 μM
Compound: tamoxifene
|
Antiproliferative activity against human MCF7 cells expressing estrogen receptor after 48 hrs by MTT assay
Antiproliferative activity against human MCF7 cells expressing estrogen receptor after 48 hrs by MTT assay
|
[PMID: 19423356] |
| MCF7 | ED50 |
5 μg/mL
Compound: TAM
|
Cytotoxicity against human MCF7 cells expressing estrogen receptor after 72 hrs by SRB assay
Cytotoxicity against human MCF7 cells expressing estrogen receptor after 72 hrs by SRB assay
|
[PMID: 19425534] |
| MCF7 | IC50 |
12 μM
Compound: tamoxifen
|
Anticancer activity against estrogen-positive human MCF7 cells after 18 hrs by MTT assay
Anticancer activity against estrogen-positive human MCF7 cells after 18 hrs by MTT assay
|
[PMID: 19446930] |
| MCF7 | IC50 |
7.65 μM
Compound: TAM
|
Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay
Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay
|
[PMID: 19740667] |
| MCF7 | IC50 |
10.9 μM
Compound: Tamoxifen
|
Cytotoxicity against human adriamycin- resistant MCF7 cells by WST-1 assay
Cytotoxicity against human adriamycin- resistant MCF7 cells by WST-1 assay
|
[PMID: 19836230] |
| MCF7 | IC50 |
11.1 μM
Compound: Tamoxifen
|
Cytotoxicity against human tamoxifen-resistant MCF7 cells by WST-1 assay
Cytotoxicity against human tamoxifen-resistant MCF7 cells by WST-1 assay
|
[PMID: 19836230] |
| MCF7 | IC50 |
11.4 μM
Compound: Tamoxifen
|
Cytotoxicity against human MCF7 cells by WST-1 assay
Cytotoxicity against human MCF7 cells by WST-1 assay
|
[PMID: 19836230] |
| MCF7 | IC50 |
1 μM
Compound: Tamoxifen
|
Antiproliferative activity against human MCF7 cells by MTT assay
Antiproliferative activity against human MCF7 cells by MTT assay
|
[PMID: 20451380] |
| MCF7 | IC50 |
8.9 μM
Compound: Tamoxifen
|
Cytotoxicity against human MCF7 cells after 24 hrs by MTT assay
Cytotoxicity against human MCF7 cells after 24 hrs by MTT assay
|
[PMID: 20605470] |
| MCF7 | IC50 |
11.8 μM
Compound: Tamoxifen
|
Anticancer activity against human MCF7 cells expressing estrogen receptor by MTT assay
Anticancer activity against human MCF7 cells expressing estrogen receptor by MTT assay
|
[PMID: 20951035] |
| MCF7 | IC50 |
8.31 μg/mL
Compound: TAM
|
Cytotoxicity against human MCF7 cells after 48 hrs by SRB assay
Cytotoxicity against human MCF7 cells after 48 hrs by SRB assay
|
[PMID: 21115211] |
| MCF7 | IC50 |
31 μM
Compound: TEM
|
Cytotoxicity activity against human MCF7 cells by MTS assay
Cytotoxicity activity against human MCF7 cells by MTS assay
|
[PMID: 21680064] |
| MCF7 | IC50 |
12.48 μM
Compound: Tamoxifen
|
Antiproliferative activity against human MCF7 cells expressing estrogen receptor after 48 hrs by MTT assay
Antiproliferative activity against human MCF7 cells expressing estrogen receptor after 48 hrs by MTT assay
|
[PMID: 21871812] |
| MCF7 | IC50 |
0.027 μM
Compound: Tamoxifen
|
Cytotoxicity against human MCF7 cells after 48 hrs by SRB assay
Cytotoxicity against human MCF7 cells after 48 hrs by SRB assay
|
[PMID: 22472045] |
| MCF7 | IC50 |
19.54 μM
Compound: Tam
|
Antiproliferative activity against human MCF7 cells assessed as inhibition of cell viability after 24 hrs by MTT assay
Antiproliferative activity against human MCF7 cells assessed as inhibition of cell viability after 24 hrs by MTT assay
|
[PMID: 22647217] |
| MCF7 | IC50 |
7.1 μM
Compound: 2
|
Cytotoxicity against human MCF7 cells after 96 hrs by SRB assay
Cytotoxicity against human MCF7 cells after 96 hrs by SRB assay
|
[PMID: 22749392] |
| MCF7 | IC50 |
7.1 μmol
Compound: 2
|
Cytotoxicity against human MCF7 cells after 96 hrs by SRB assay
Cytotoxicity against human MCF7 cells after 96 hrs by SRB assay
|
[PMID: 22749392] |
| MCF7 | IC50 |
8.6 μM
Compound: Tamoxifen
|
Cytotoxicity against human MCF7 cells after 72 hrs by WST1 assay in presence of 20% FBS
Cytotoxicity against human MCF7 cells after 72 hrs by WST1 assay in presence of 20% FBS
|
[PMID: 22901895] |
| MCF7 | IC50 |
11.44 μM
Compound: Tamoxifen
|
Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay
Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay
|
[PMID: 23022281] |
| MCF7 | IC50 |
1.82 μM
Compound: TAMOX, TAM
|
Cytotoxicity against human MCF7 cells after 48 hrs by sulforhodamine B assay
Cytotoxicity against human MCF7 cells after 48 hrs by sulforhodamine B assay
|
[PMID: 23123017] |
| MCF7 | IC50 |
5.5 μM
Compound: TAM
|
Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay
Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay
|
[PMID: 23287057] |
| MCF7 | GI50 |
11.2 μM
Compound: Tamoxifen
|
Growth inhibition of estrogen-dependent human MCF7 cells
Growth inhibition of estrogen-dependent human MCF7 cells
|
[PMID: 23403084] |
| MCF7 | IC50 |
200 nM
Compound: Tamoxifen
|
Antagonist activity at ERalpha receptor in human MCF7 cells assessed as inhibition of cell growth after 6 days by crystal violet staining method
Antagonist activity at ERalpha receptor in human MCF7 cells assessed as inhibition of cell growth after 6 days by crystal violet staining method
|
[PMID: 23448346] |
| MCF7 | GI50 |
12 μM
Compound: 1
|
Antiproliferative activity against human MCF7 cells after 72 hrs by trypan blue assay
Antiproliferative activity against human MCF7 cells after 72 hrs by trypan blue assay
|
[PMID: 23735829] |
| MCF7 | IC50 |
15.6 μM
Compound: Tamoxifen
|
Cytotoxicity against human MCF7 cells expressing ERalpha and ERbeta assessed as growth inhibition after 72 hrs by MTT assay
Cytotoxicity against human MCF7 cells expressing ERalpha and ERbeta assessed as growth inhibition after 72 hrs by MTT assay
|
[PMID: 23786452] |
| MCF7 | IC50 |
5.19 μM
Compound: Tamoxifen
|
Cytotoxicity against human MCF7 cells by SRB assay
Cytotoxicity against human MCF7 cells by SRB assay
|
[PMID: 23806014] |
| MCF7 | IC50 |
12.35 μM
Compound: Tamoxifen
|
Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay
Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay
|
[PMID: 23830503] |
| MCF7 | IC50 |
27.96 μM
Compound: 1, TAM
|
Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay
Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay
|
[PMID: 23860592] |
| MCF7 | IC50 |
0.794 μM
Compound: Tamoxifen
|
Cytotoxicity against human MCF7 cells after 5 days
Cytotoxicity against human MCF7 cells after 5 days
|
[PMID: 23864928] |
| MCF7 | IC50 |
15.2 μM
Compound: 6
|
Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay
Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay
|
[PMID: 23880359] |
| MCF7 | IC50 |
13.45 μM
Compound: Tamoxifen
|
Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay
Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay
|
[PMID: 23902804] |
| MCF7 | IC50 |
9 μM
Compound: TAM
|
Cytotoxicity against human MCF7 cells after 24 hrs by MTT assay
Cytotoxicity against human MCF7 cells after 24 hrs by MTT assay
|
[PMID: 24457094] |
| MCF7 | IC50 |
8 μg/mL
Compound: Tamoxifen
|
Cytotoxicity against human MCF7 cells after 48 hrs by sulforhodamine B assay
Cytotoxicity against human MCF7 cells after 48 hrs by sulforhodamine B assay
|
[PMID: 24576797] |
| MCF7 | IC50 |
1.89 μM
Compound: Tamoxifen
|
Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay
Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay
|
[PMID: 24721727] |
| MCF7 | IC50 |
6 μM
Compound: Tamoxifen
|
Antiproliferative activity against human MCF7 cells after 24 hrs by MTT assay
Antiproliferative activity against human MCF7 cells after 24 hrs by MTT assay
|
[PMID: 24880230] |
| MCF7 | IC50 |
64.3 μM
Compound: Tamoxifen
|
Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 96 hrs by MTT assay
Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 96 hrs by MTT assay
|
[PMID: 25164760] |
| MCF7 | IC50 |
82.5 μM
Compound: Tamoxifen
|
Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 48 hrs by MTT assay
Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 48 hrs by MTT assay
|
[PMID: 25164760] |
| MCF7 | IC50 |
4.67 μM
Compound: Tam
|
Antiproliferative activity human ER-positive MCF7 cells after 2 days by MTT assay
Antiproliferative activity human ER-positive MCF7 cells after 2 days by MTT assay
|
[PMID: 25222876] |
| MCF7 | IC50 |
4.1 μM
Compound: 2
|
Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay
Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay
|
[PMID: 25369367] |
| MCF7 | IC50 |
2.1 μM
Compound: tamoxifen
|
Antiproliferative activity against human MCF7 cells after 5 days by WST-8 assay
Antiproliferative activity against human MCF7 cells after 5 days by WST-8 assay
|
[PMID: 25614118] |
| MCF7 | IC50 |
18.71 μM
Compound: tamoxifen
|
Antiproliferative activity against human MCF7 cells assessed as reduction in cell growth incubated at 37 degC for 3 days by resazurin microplate assay
Antiproliferative activity against human MCF7 cells assessed as reduction in cell growth incubated at 37 degC for 3 days by resazurin microplate assay
|
[PMID: 25734623] |
| MCF7 | IC50 |
3.8 μM
Compound: Tamoxifen
|
Cytotoxicity against human MCF7 cells assessed as cell viability by MTT assay
Cytotoxicity against human MCF7 cells assessed as cell viability by MTT assay
|
[PMID: 26079090] |
| MCF7 | GI50 |
8 μM
Compound: Tamoxifen
|
Anti-proliferative activity against human MCF7 cells incubated for 48 hrs by SRB assay
Anti-proliferative activity against human MCF7 cells incubated for 48 hrs by SRB assay
|
[PMID: 26163220] |
| MCF7 | GI50 |
1.58 μM
Compound: TAM
|
Cytotoxicity against human MCF7 cells assessed as growth inhibition after 48 hrs by SRB assay
Cytotoxicity against human MCF7 cells assessed as growth inhibition after 48 hrs by SRB assay
|
[PMID: 26896706] |
| MCF7 | IC50 |
4.4 μM
Compound: TAM
|
Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay
Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay
|
[PMID: 26896706] |
| MCF7 | IC50 |
50 μM
Compound: Tamoxifen
|
Cytotoxicity against human ER-positive MCF7 cells assessed as cell viability after 72 hrs by MTT assay
Cytotoxicity against human ER-positive MCF7 cells assessed as cell viability after 72 hrs by MTT assay
|
[PMID: 26972118] |
| MCF7 | GI50 |
6.5 μM
Compound: 1
|
Cytotoxicity against human MCF7 cells assessed as cell growth inhibition after 72 hrs by trypan blue assay
Cytotoxicity against human MCF7 cells assessed as cell growth inhibition after 72 hrs by trypan blue assay
|
[PMID: 27128175] |
| MCF7 | IC50 |
13.7 μM
Compound: Tamoxifen
|
Antiproliferative activity against human MCF7 cells
Antiproliferative activity against human MCF7 cells
|
[PMID: 27155469] |
| MCF7 | IC50 |
5.3 μM
Compound: Tamoxifen
|
Antiproliferative activity against human MCF7 cells incubated for 48 hrs by MTT assay
Antiproliferative activity against human MCF7 cells incubated for 48 hrs by MTT assay
|
[PMID: 27176944] |
| MCF7 | IC50 |
6.99 μM
Compound: Tamoxifen
|
Cytotoxicity against human MCF7 cells by resazurin microplate assay
Cytotoxicity against human MCF7 cells by resazurin microplate assay
|
[PMID: 27228159] |
| MCF7 | IC50 |
19.33 μM
Compound: Tamoxifen
|
Cytotoxicity against human MCF7 cells assessed as reduction in cell viability by resazurin microplate assay
Cytotoxicity against human MCF7 cells assessed as reduction in cell viability by resazurin microplate assay
|
[PMID: 27311894] |
| MCF7 | IC50 |
4.1 μM
Compound: Tamoxifen
|
Antiproliferative activity against ER-positive human MCF7 cells assessed as reduction in cell viability measured after 72 hrs by AlamarBlue assay
Antiproliferative activity against ER-positive human MCF7 cells assessed as reduction in cell viability measured after 72 hrs by AlamarBlue assay
|
[PMID: 27407030] |
| MCF7 | IC50 |
18.18 μM
Compound: Tamoxifen
|
Anticancer activity against human ER-positive MCF7 cells measured after 48 hrs by SRB assay
Anticancer activity against human ER-positive MCF7 cells measured after 48 hrs by SRB assay
|
[PMID: 27671497] |
| MCF7 | EC50 |
0.11 nM
Compound: TAM Z
|
Effective dose for [3H]- estradiol against proliferation of MCF-7 cells
Effective dose for [3H]- estradiol against proliferation of MCF-7 cells
|
[PMID: 2769681] |
| MCF7 | IC50 |
219 nM
Compound: TAM Z
|
In vitro inhibition of MCF-7 cell proliferation compared to 0.1 nM [3H]-estradiol.
In vitro inhibition of MCF-7 cell proliferation compared to 0.1 nM [3H]-estradiol.
|
[PMID: 2769681] |
| MCF7 | GI50 |
6.8 μM
Compound: Tamoxifen
|
Cytotoxicity against human MCF7 cells assessed as growth inhibition after 120 hrs by MTT assay
Cytotoxicity against human MCF7 cells assessed as growth inhibition after 120 hrs by MTT assay
|
[PMID: 28152429] |
| MCF7 | IC50 |
4.1 μM
Compound: 2a
|
Antiproliferative activity against ER-dependent human MCF7 cells after 72 hrs by MTT assay
Antiproliferative activity against ER-dependent human MCF7 cells after 72 hrs by MTT assay
|
[PMID: 28426931] |
| MCF7 | IC50 |
4.4 μM
Compound: 2a
|
Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 5 days by SRB assay
Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 5 days by SRB assay
|
[PMID: 28426931] |
| MCF7 | IC50 |
3.99 μg/mL
Compound: Tamoxifen
|
Inhibition of estradiol-induced proliferation in human MCF7 cells after 72 hrs by Cell-titer-Glo assay
Inhibition of estradiol-induced proliferation in human MCF7 cells after 72 hrs by Cell-titer-Glo assay
|
[PMID: 28442256] |
| MCF7 | IC50 |
11.35 μM
Compound: Tamoxifen
|
Antiproliferative activity against ER positive human MCF7 cells after 48 hrs by MTT assay
Antiproliferative activity against ER positive human MCF7 cells after 48 hrs by MTT assay
|
[PMID: 28460819] |
| MCF7 | IC50 |
21.57 μM
Compound: Tamoxifen
|
Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 48 hrs by SRB assay
Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 48 hrs by SRB assay
|
[PMID: 28505536] |
| MCF7 | IC50 |
7.94 μM
Compound: Tamoxifen
|
Cytotoxicity against human MCF7 cells after 72 hrs by resazurin based fluorescence assay
Cytotoxicity against human MCF7 cells after 72 hrs by resazurin based fluorescence assay
|
[PMID: 28927795] |
| MCF7 | IC50 |
14.35 μM
Compound: Tamoxifen
|
Cytotoxicity in human MCF7 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
Cytotoxicity in human MCF7 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
|
[PMID: 28942113] |
| MCF7 | IC50 |
8.12 μM
Compound: Tamoxifen
|
Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay
Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay
|
[PMID: 29054359] |
| MCF7 | IC50 |
2.7 μM
Compound: Tamoxifen
|
Cytostatic activity against human MCF7 cells
Cytostatic activity against human MCF7 cells
|
[PMID: 29207335] |
| MCF7 | IC50 |
5.3 μM
Compound: Tamoxifen
|
Growth inhibition of human MCF7 cells after 72 hrs by MTT assay
Growth inhibition of human MCF7 cells after 72 hrs by MTT assay
|
[PMID: 29220789] |
| MCF7 | IC50 |
19.5 μM
Compound: Tamoxifen
|
Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay
Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay
|
[PMID: 29482944] |
| MCF7 | IC50 |
15.46 μM
Compound: Tamoxifen
|
Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay
Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay
|
[PMID: 29587221] |
| MCF7 | IC50 |
8.61 μM
Compound: Tamoxifen
|
Cytotoxicity against human MCF7 cells preincubated for 4 hrs followed by incubation in compound free media for 24 hrs by MTT assay
Cytotoxicity against human MCF7 cells preincubated for 4 hrs followed by incubation in compound free media for 24 hrs by MTT assay
|
[PMID: 29605808] |
| MCF7 | IC50 |
7.09 μM
Compound: Tamoxifen
|
Antiproliferative activity against human MCF7 cells after 24 hrs by MTT assay
Antiproliferative activity against human MCF7 cells after 24 hrs by MTT assay
|
[PMID: 30360952] |
| MCF7 | IC50 |
16.7 μM
Compound: Tamoxifen
|
Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay
Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay
|
[PMID: 30384047] |
| MCF7 | IC50 |
42.4 μM
Compound: Tamoxifen
|
Antiproliferative activity against human MCF7 cells after 24 hrs by MTT assay
Antiproliferative activity against human MCF7 cells after 24 hrs by MTT assay
|
[PMID: 30731397] |
| MCF7 | IC50 |
4 μM
Compound: TAM
|
Cytotoxicity against human MCF7 Cells after 48 hrs by neutral red dye-based assay
Cytotoxicity against human MCF7 Cells after 48 hrs by neutral red dye-based assay
|
[PMID: 31129455] |
| MCF7 | IC50 |
10.87 μM
Compound: Tamoxifen
|
Antiproliferative activity against human MCF7 cells by MTT assay
Antiproliferative activity against human MCF7 cells by MTT assay
|
[PMID: 31546197] |
| MCF7 | IC50 |
25 μM
Compound: Tamoxifen
|
Antiproliferative activity against human MCF7 cells by fluorescence based viable cell counting method
Antiproliferative activity against human MCF7 cells by fluorescence based viable cell counting method
|
[PMID: 31610378] |
| MCF7 | IC50 |
22.6 μM
Compound: TAM
|
Cytotoxicity against human MCF7 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
Cytotoxicity against human MCF7 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
|
[PMID: 31620225] |
| MCF7 | IC50 |
25 μM
Compound: Tamoxifen
|
Antiproliferative activity against human MCF7cells assessed as reduction in cell viability after 24 hrs by DAPI/propidium iodide staining based assay
Antiproliferative activity against human MCF7cells assessed as reduction in cell viability after 24 hrs by DAPI/propidium iodide staining based assay
|
[PMID: 31673312] |
| MCF7 | IC50 |
1.31 μg/mL
Compound: Tamoxifen
|
Antiproliferative activity against human MCF-7 cells assessed as inhibition of colony formation measured after 3 weeks by crystal violet staining based soft agar colony formation assay
Antiproliferative activity against human MCF-7 cells assessed as inhibition of colony formation measured after 3 weeks by crystal violet staining based soft agar colony formation assay
|
[PMID: 31884407] |
| MCF7 | IC50 |
11.55 μM
Compound: Tamoxifen
|
Antiproliferative activity against human MCF-7 cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay
Antiproliferative activity against human MCF-7 cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay
|
[PMID: 31884407] |
| MCF7 | IC50 |
3.53 μM
Compound: Tamoxifen
|
Anticancer activity against human MCF7 cells
Anticancer activity against human MCF7 cells
|
[PMID: 31926469] |
| MCF7 | IC50 |
4.12 μM
Compound: Tamoxifen
|
Antiproliferative activity against human MCF7 cells assessed as inhibition of cell viability after 72 hrs by MTT assay
Antiproliferative activity against human MCF7 cells assessed as inhibition of cell viability after 72 hrs by MTT assay
|
[PMID: 31987694] |
| MCF7 | IC50 |
25 μM
Compound: Tamoxifen
|
Cytotoxicity against human MCF7 cells
Cytotoxicity against human MCF7 cells
|
[PMID: 32386856] |
| MCF7 | IC50 |
9 μM
Compound: Tamoxifen
|
Anticancer activity against human MCF7 cells assessed as inhibition of cell growth incubated for 24 hrs by MTT assay
Anticancer activity against human MCF7 cells assessed as inhibition of cell growth incubated for 24 hrs by MTT assay
|
[PMID: 32731188] |
| MCF7 | IC50 |
8.38 μg/mL
Compound: Tamoxifen
|
Anticancer activity against human MCF7 cells assessed a cell growth inhibition incubated for 48 hrs by SRB assay
Anticancer activity against human MCF7 cells assessed a cell growth inhibition incubated for 48 hrs by SRB assay
|
[PMID: 32771798] |
| MCF7 | IC50 |
54 μM
Compound: Tamoxifen
|
Antiproliferative activity against human MCF7 cells after 24 hrs by MTT assay
Antiproliferative activity against human MCF7 cells after 24 hrs by MTT assay
|
[PMID: 33234343] |
| MCF7 | IC50 |
30 nM
Compound: Tam
|
Antiproliferative activity against human MCF7 cells assessed as inhibition of cell growth incubated for 6 days by SRB assay
Antiproliferative activity against human MCF7 cells assessed as inhibition of cell growth incubated for 6 days by SRB assay
|
[PMID: 33257172] |
| MCF7 | IC50 |
15.21 μM
Compound: Tamoxifen
|
Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay
Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay
|
[PMID: 33340662] |
| MCF7 | IC50 |
6.3 μM
Compound: Tamoxifen
|
Cytotoxicity against ER and PR-positive human MCF7 cells assessed as reduction in colony formation incubated for 7 days by crystal violet staining based assay
Cytotoxicity against ER and PR-positive human MCF7 cells assessed as reduction in colony formation incubated for 7 days by crystal violet staining based assay
|
[PMID: 33373820] |
| MCF7 | IC50 |
9.6 μM
Compound: Tamoxifen
|
Cytotoxicity against ER and PR-positive human MCF7 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
Cytotoxicity against ER and PR-positive human MCF7 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
|
[PMID: 33373820] |
| MCF7 | IC50 |
13.7 μM
Compound: Tamoxifen
|
Antiproliferative activity against human MCF7 cells by MTT reduction assay
Antiproliferative activity against human MCF7 cells by MTT reduction assay
|
[PMID: 33421712] |
| MCF7 | IC50 |
20 nM
Compound: 7
|
Cytotoxicity against human MCF7 cells assessed as inhibition of cell growth measured after 72 hrs by MTT assay
Cytotoxicity against human MCF7 cells assessed as inhibition of cell growth measured after 72 hrs by MTT assay
|
[PMID: 33479633] |
| MCF7 | IC50 |
19.2 μM
Compound: Tamoxifen
|
Cytotoxicity against human MCF7 cells assessed as reduction in cell viability by resazurin based fluorescence assay
Cytotoxicity against human MCF7 cells assessed as reduction in cell viability by resazurin based fluorescence assay
|
[PMID: 33852304] |
| MCF7 | IC50 |
5.62 μM
Compound: Tamoxifen
|
Cytotoxicity against human MCF7 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay
Cytotoxicity against human MCF7 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay
|
[PMID: 33894490] |
| MCF7 | IC50 |
8.42 μM
Compound: TAM
|
Cytotoxicity against human MCF7 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
Cytotoxicity against human MCF7 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
|
[PMID: 34153643] |
| MCF7 | EC50 |
>200 nM
Compound: 2
|
Antiproliferative activity against human MCF-7 cells incubated for 72 hrs by Cell-titer Glo assay
Antiproliferative activity against human MCF-7 cells incubated for 72 hrs by Cell-titer Glo assay
|
[PMID: 34251202] |
| MCF7 | IC50 |
5.4 μM
Compound: Tamoxifen
|
Antiproliferative activity against human MCF7 cells assessed as inhibition of cell growth incubated for 24 hrs by MTT assay
Antiproliferative activity against human MCF7 cells assessed as inhibition of cell growth incubated for 24 hrs by MTT assay
|
[PMID: 34726897] |
| MCF7 | IC50 |
8.53 μM
Compound: 1
|
Antiproliferative activity against human MCF7 cells assessed as cell viability after 24 hrs by MTT assay
Antiproliferative activity against human MCF7 cells assessed as cell viability after 24 hrs by MTT assay
|
[PMID: 35276362] |
| MCF7 | IC50 |
8.5 μg/mL
Compound: Tamoxifen
|
Cytotoxicity against human MCF7 cells by SRB assay
Cytotoxicity against human MCF7 cells by SRB assay
|
[PMID: 36325400] |
| MCF7 | GI50 |
<10 μg/mL
Compound: Tmx
|
Growth inhibition of human MCF7 cells assessed as cell growth inhibition by SRB assay
Growth inhibition of human MCF7 cells assessed as cell growth inhibition by SRB assay
|
[PMID: 36481599] |
| MCF7 | IC50 |
20.24 μM
Compound: Tmx
|
Anticancer activity against human MCF7 cells assessed as cell growth inhibition measured after 24 hrs by MTT assay
Anticancer activity against human MCF7 cells assessed as cell growth inhibition measured after 24 hrs by MTT assay
|
[PMID: 36481599] |
| MCF7 | IC50 |
<1000 μM
Compound: Tamoxifen
|
Antiproliferative activity against human MCF7 cells assessed as inhibition of cell growth incubated for 72 hrs by Hoechst 33342/propidium iodide staining based fluorescence analysis
Antiproliferative activity against human MCF7 cells assessed as inhibition of cell growth incubated for 72 hrs by Hoechst 33342/propidium iodide staining based fluorescence analysis
|
[PMID: 36603398] |
| MCF7 | IC50 |
10.2 μM
Compound: Tamoxifen
|
Antiproliferative activity against human MCF7 cells assessed as inhibition of cell growth measured after 72 hrs by SRB assay
Antiproliferative activity against human MCF7 cells assessed as inhibition of cell growth measured after 72 hrs by SRB assay
|
[PMID: 36780831] |
| MCF7 | IC50 |
5.8 μM
Compound: Tamoxifen
|
Induction of apoptosis in human MCF7 cells in presence of EGCG at 50 uM
Induction of apoptosis in human MCF7 cells in presence of EGCG at 50 uM
|
[PMID: 36780831] |
| MCF7 | IC50 |
50 μM
Compound: Tamoxifen
|
Antiproliferative activity against human MCF7 cells assessed as cell growth inhibition measured after 24 hrs by MTT assay
Antiproliferative activity against human MCF7 cells assessed as cell growth inhibition measured after 24 hrs by MTT assay
|
[PMID: 36846377] |
| MCF7 | IC50 |
50 μM
Compound: Tamoxifen
|
Antiproliferative activity against human MCF7 cells assessed as inhibition of cell proliferation incubated for 24 hrs by MTT assay
Antiproliferative activity against human MCF7 cells assessed as inhibition of cell proliferation incubated for 24 hrs by MTT assay
|
[PMID: 36846377] |
| MCF7 | IC50 |
2.33 μM
Compound: 1
|
Antiproliferative activity against human MCF7 cells assessed as cell growth inhibition incubated for 5 days by MTT assay
Antiproliferative activity against human MCF7 cells assessed as cell growth inhibition incubated for 5 days by MTT assay
|
[PMID: 37019030] |
| MCF7 | IC50 |
10.74 μM
Compound: Tamoxifen
|
Cytotoxicity against human MCF7 cells incubated for 72 hrs by Sulphorhodamine assay
Cytotoxicity against human MCF7 cells incubated for 72 hrs by Sulphorhodamine assay
|
[PMID: 37146520] |
| MCF7 | IC50 |
10 μM
Compound: 1; TMX
|
Antiproliferative activity against human MCF7 cells assessed as inhibition of cell growth
Antiproliferative activity against human MCF7 cells assessed as inhibition of cell growth
|
[PMID: 37484572] |
| MCF7 | IC50 |
14.096 μM
Compound: 1; TMX
|
Anticancer activity against human MCF7 cells assessed as inhibition of cell growth incubated for 48 hrs by CVDK-8 method
Anticancer activity against human MCF7 cells assessed as inhibition of cell growth incubated for 48 hrs by CVDK-8 method
|
[PMID: 37484572] |
| MCF7 | IC50 |
25.787 μM
Compound: 1; TMX
|
Anticancer activity against human MCF7 cells assessed as inhibition of cell growth incubated for 24 hrs by CVDK-8 method
Anticancer activity against human MCF7 cells assessed as inhibition of cell growth incubated for 24 hrs by CVDK-8 method
|
[PMID: 37484572] |
| MCF7 | IC50 |
22.47 μM
Compound: Tamoxifen
|
Antiproliferative activity against human MCF7 cells
Antiproliferative activity against human MCF7 cells
|
[PMID: 37875056] |
| MCF7 | IC50 |
8.12 μM
Compound: TAM
|
Antiproliferative activity against estrogen receptor positive human MCF7 cells assessed as inhibition of cell viability by MTT assay
Antiproliferative activity against estrogen receptor positive human MCF7 cells assessed as inhibition of cell viability by MTT assay
|
[PMID: 38729318] |
| MCF7 | IC50 |
1.56 μM
Compound: Tamoxifen
|
Antiproliferative activity against human MCF7 cells incubated for 5 days by MTT assay
Antiproliferative activity against human MCF7 cells incubated for 5 days by MTT assay
|
[PMID: 38870830] |
| MCF7 | IC50 |
12.6 μM
Compound: Tamoxifen
|
Antiproliferative activity against human MCF7 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay
Antiproliferative activity against human MCF7 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay
|
[PMID: 38911170] |
| MCF7 | IC50 |
14 μM
Compound: 1
|
In vitro cytotoxicity against hormone-responsive MCF-7 cell line.
In vitro cytotoxicity against hormone-responsive MCF-7 cell line.
|
[PMID: 7830266] |
| MCF7 | IC50 |
0.14 μM
Compound: tamoxifen (TAM)
|
Anti-proliferative activity against estrogen-responsive human breast cancer cell line MCF-7 in the presence of ER at a 10e-4 uM concentration of estradiol
Anti-proliferative activity against estrogen-responsive human breast cancer cell line MCF-7 in the presence of ER at a 10e-4 uM concentration of estradiol
|
[PMID: 8784443] |
| MCF7 | IC50 |
19 μM
Compound: tamoxifen (TAM)
|
Inhibition of 10e-4 uM estradiol induced estrogen receptor positive MCF-7 human breast cancer cell proliferation
Inhibition of 10e-4 uM estradiol induced estrogen receptor positive MCF-7 human breast cancer cell proliferation
|
[PMID: 8784443] |
| MCF7 | IC50 |
8 μM
Compound: Tam Z
|
Cytostaticity against MCF-7 cells in the presence of 1 uMolar E2 (estradiol)
Cytostaticity against MCF-7 cells in the presence of 1 uMolar E2 (estradiol)
|
[PMID: 9089332] |
| MCF7 | IC50 |
481 nM
Compound: 1 (tamoxifen)
|
Inhibition of estrogen-induced proliferation in human MCF-7 breast cancer cells
Inhibition of estrogen-induced proliferation in human MCF-7 breast cancer cells
|
[PMID: 9154963] |
| MCF7 | IC50 |
0.15 μM
Compound: Tamoxifen, ICI-46474
|
Inhibition of estrogen receptor positive MCF-7 human breast cancer cell proliferation
Inhibition of estrogen receptor positive MCF-7 human breast cancer cell proliferation
|
[PMID: 9357519] |
| MCF7 | IC50 |
55.5 μM
Compound: Tamoxifen
|
Cytotoxicity against Homo sapiens (human) MCF7 cells assessed as inhibition of cell proliferation after 72 hr by MTT assay
Cytotoxicity against Homo sapiens (human) MCF7 cells assessed as inhibition of cell proliferation after 72 hr by MTT assay
|
10.1007/s00044-012-0391-5 |
| MCF7 | IC50 |
17 μM
Compound: Tamoxifen
|
In vitro inhibition of estrogen receptor positive MCF-7 human mammary carcinoma cell proliferation
In vitro inhibition of estrogen receptor positive MCF-7 human mammary carcinoma cell proliferation
|
10.1016/0960-894X(95)00381-3 |
| MCF7 | IC50 |
10 μg/mL
Compound: 125
|
Antiproliferative activity against human MCF7 cells
Antiproliferative activity against human MCF7 cells
|
10.1039/C2MD20089A |
| MCF7 | IC50 |
12.5 μM
Compound: Tam
|
Cytotoxicity against human MCF7 cells expressing ER after 48 hrs by MTT assay
Cytotoxicity against human MCF7 cells expressing ER after 48 hrs by MTT assay
|
10.1039/C4MD00289J |
| MCF7S | IC50 |
7200 nM
Compound: 1a
|
Inhibition of [3H]thymidine incorporation into MCF-7 cells
Inhibition of [3H]thymidine incorporation into MCF-7 cells
|
[PMID: 1573630] |
| MDA-MB-231 | IC50 |
19 μM
Compound: Tamoxifen
|
Inhibitory concentration against MDA-MB-231 (ER-) cell line using SRB assay
Inhibitory concentration against MDA-MB-231 (ER-) cell line using SRB assay
|
[PMID: 12565971] |
| MDA-MB-231 | IC50 |
80 nM
Compound: Tamoxifen
|
Inhibition of estrogen receptor negative MDA-MB-231 breast cancer cell proliferation
Inhibition of estrogen receptor negative MDA-MB-231 breast cancer cell proliferation
|
[PMID: 14971899] |
| MDA-MB-231 | ED50 |
8.5 μg/mL
Compound: TAM
|
Cytotoxicity against human MDA-MB-231 cells lacking ER
Cytotoxicity against human MDA-MB-231 cells lacking ER
|
[PMID: 16942038] |
| MDA-MB-231 | IC50 |
20 μM
Compound: tamoxifene
|
Antiproliferative activity against human estrogen receptor deficient MDA-MB-231 cells after 48 hrs by MTT assay
Antiproliferative activity against human estrogen receptor deficient MDA-MB-231 cells after 48 hrs by MTT assay
|
[PMID: 19423356] |
| MDA-MB-231 | IC50 |
24 μM
Compound: tamoxifen
|
Anticancer activity against estrogen-positive human MDA-MB-231 cells after 18 hrs by MTT assay
Anticancer activity against estrogen-positive human MDA-MB-231 cells after 18 hrs by MTT assay
|
[PMID: 19446930] |
| MDA-MB-231 | IC50 |
9.86 μM
Compound: TAM
|
Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by MTT assay
Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by MTT assay
|
[PMID: 19740667] |
| MDA-MB-231 | IC50 |
12.4 μM
Compound: Tamoxifen
|
Cytotoxicity against human MDA-MB-231 cells by WST-1 assay
Cytotoxicity against human MDA-MB-231 cells by WST-1 assay
|
[PMID: 19836230] |
| MDA-MB-231 | IC50 |
0.66 μM
Compound: Tamoxifen
|
Antiproliferative activity against human MDA-MB-231 cells by MTT assay
Antiproliferative activity against human MDA-MB-231 cells by MTT assay
|
[PMID: 20451380] |
| MDA-MB-231 | IC50 |
10 μM
Compound: Tamoxifen
|
Cytotoxicity against human MDA-MB-231 cells after 24 hrs by MTT assay
Cytotoxicity against human MDA-MB-231 cells after 24 hrs by MTT assay
|
[PMID: 20605470] |
| MDA-MB-231 | IC50 |
18.9 μM
Compound: Tamoxifen
|
Antiproliferative activity against estrogen receptor-deficient human MDA-MB-231 cells expressing estrogen receptor after 48 hrs by MTT assay
Antiproliferative activity against estrogen receptor-deficient human MDA-MB-231 cells expressing estrogen receptor after 48 hrs by MTT assay
|
[PMID: 21871812] |
| MDA-MB-231 | IC50 |
12.41 μM
Compound: Tamoxifen
|
Cytotoxicity against human MDA-MB-231 cells after 48 hrs by MTT assay
Cytotoxicity against human MDA-MB-231 cells after 48 hrs by MTT assay
|
[PMID: 23022281] |
| MDA-MB-231 | IC50 |
11.4 μM
Compound: TAM
|
Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by MTT assay
Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by MTT assay
|
[PMID: 23287057] |
| MDA-MB-231 | GI50 |
18.8 μM
Compound: Tamoxifen
|
Growth inhibition of estrogen-independent human MDA-MB-231 cells
Growth inhibition of estrogen-independent human MDA-MB-231 cells
|
[PMID: 23403084] |
| MDA-MB-231 | IC50 |
17 μM
Compound: Tamoxifen
|
Cytotoxicity against ERalpha and ERbeta-deficient human MDA-MB-231 cells assessed as growth inhibition after 72 hrs by MTT assay
Cytotoxicity against ERalpha and ERbeta-deficient human MDA-MB-231 cells assessed as growth inhibition after 72 hrs by MTT assay
|
[PMID: 23786452] |
| MDA-MB-231 | IC50 |
64.85 μM
Compound: 1, TAM
|
Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by MTT assay
Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by MTT assay
|
[PMID: 23860592] |
| MDA-MB-231 | IC50 |
10 μM
Compound: TAM
|
Cytotoxicity against human MDA-MB-231 cells after 24 hrs by MTT assay
Cytotoxicity against human MDA-MB-231 cells after 24 hrs by MTT assay
|
[PMID: 24457094] |
| MDA-MB-231 | IC50 |
14 μM
Compound: Tamoxifen
|
Antiproliferative activity against human MDA-MB-231 cells after 24 hrs by MTT assay
Antiproliferative activity against human MDA-MB-231 cells after 24 hrs by MTT assay
|
[PMID: 24880230] |
| MDA-MB-231 | IC50 |
75 μM
Compound: Tamoxifen
|
Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability after 96 hrs by MTT assay
Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability after 96 hrs by MTT assay
|
[PMID: 25164760] |
| MDA-MB-231 | IC50 |
84.6 μM
Compound: Tamoxifen
|
Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability after 48 hrs by MTT assay
Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability after 48 hrs by MTT assay
|
[PMID: 25164760] |
| MDA-MB-231 | IC50 |
38.97 μM
Compound: Tam
|
Antiproliferative activity human ER-negative MDA-MB-231 cells after 2 days by MTT assay
Antiproliferative activity human ER-negative MDA-MB-231 cells after 2 days by MTT assay
|
[PMID: 25222876] |
| MDA-MB-231 | IC50 |
>50 μM
Compound: Tamoxifen
|
Cytotoxicity against human ER-negative MDA-MB-231 cells assessed as cell viability after 72 hrs by MTT assay
Cytotoxicity against human ER-negative MDA-MB-231 cells assessed as cell viability after 72 hrs by MTT assay
|
[PMID: 26972118] |
| MDA-MB-231 | IC50 |
17.9 μM
Compound: Tamoxifen
|
Antiproliferative activity against human MDA-MB-231 cells
Antiproliferative activity against human MDA-MB-231 cells
|
[PMID: 27155469] |
| MDA-MB-231 | IC50 |
13.9 μM
Compound: Tamoxifen
|
Antiproliferative activity against human MDA-MB-231 cells incubated for 48 hrs by MTT assay
Antiproliferative activity against human MDA-MB-231 cells incubated for 48 hrs by MTT assay
|
[PMID: 27176944] |
| MDA-MB-231 | GI50 |
15.1 μM
Compound: Tamoxifen
|
Cytotoxicity against human MDA-MB-231 cells assessed as growth inhibition after 120 hrs by MTT assay
Cytotoxicity against human MDA-MB-231 cells assessed as growth inhibition after 120 hrs by MTT assay
|
[PMID: 28152429] |
| MDA-MB-231 | IC50 |
7.85 μg/mL
Compound: Tamoxifen
|
Inhibition of estradiol-induced proliferation in human MDA-MB-231 cells after 72 hrs by Cell-titer-Glo assay
Inhibition of estradiol-induced proliferation in human MDA-MB-231 cells after 72 hrs by Cell-titer-Glo assay
|
[PMID: 28442256] |
| MDA-MB-231 | IC50 |
9.96 μM
Compound: Tamoxifen
|
Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by MTT assay
Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by MTT assay
|
[PMID: 29054359] |
| MDA-MB-231 | IC50 |
47.1 μM
Compound: Tamoxifen
|
Antiproliferative activity against human MDA-MB-231 cells after 24 hrs by MTT assay
Antiproliferative activity against human MDA-MB-231 cells after 24 hrs by MTT assay
|
[PMID: 30360952] |
| MDA-MB-231 | IC50 |
18.08 μM
Compound: Tamoxifen
|
Binding affinity to rRNA-A site in human MDA-MB-231 cells assessed as inhibition of protein translation
Binding affinity to rRNA-A site in human MDA-MB-231 cells assessed as inhibition of protein translation
|
[PMID: 30530174] |
| MDA-MB-231 | GI50 |
0.24 μM
Compound: Tamoxifen
|
Cytotoxicity against human MDA-MB-231 cells
Cytotoxicity against human MDA-MB-231 cells
|
[PMID: 31200236] |
| MDA-MB-231 | IC50 |
11.2 μM
Compound: Tamoxifen
|
Antiproliferative activity against human MDA-MB-231 cells by MTT assay
Antiproliferative activity against human MDA-MB-231 cells by MTT assay
|
[PMID: 31546197] |
| MDA-MB-231 | GI50 |
0.12 μM
Compound: Tamoxifen
|
Growth inhibition of human MDA-MB-231 cells
Growth inhibition of human MDA-MB-231 cells
|
[PMID: 31605865] |
| MDA-MB-231 | IC50 |
>20 μM
Compound: Tamoxifen
|
Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay
Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay
|
[PMID: 31884407] |
| MDA-MB-231 | IC50 |
69.7 μM
Compound: Tamoxifen
|
Antiproliferative activity against human MDA-MB-231 cells assessed as cell viability after 24 hrs
Antiproliferative activity against human MDA-MB-231 cells assessed as cell viability after 24 hrs
|
[PMID: 33139111] |
| MDA-MB-231 | IC50 |
75 μM
Compound: Tamoxifen
|
Antiproliferative activity against human MDA-MB-231 cells after 24 hrs by MTT assay
Antiproliferative activity against human MDA-MB-231 cells after 24 hrs by MTT assay
|
[PMID: 33234343] |
| MDA-MB-231 | IC50 |
35.8 μM
Compound: Tamoxifen
|
Cytotoxicity against human MDA-MB-231 cells after 48 hrs by MTT assay
Cytotoxicity against human MDA-MB-231 cells after 48 hrs by MTT assay
|
[PMID: 33340662] |
| MDA-MB-231 | IC50 |
5.9 μM
Compound: Tamoxifen
|
Cytotoxicity against ER-negative human MDA-MB-231 cells assessed as reduction in colony formation incubated for 7 days by crystal violet staining based assay
Cytotoxicity against ER-negative human MDA-MB-231 cells assessed as reduction in colony formation incubated for 7 days by crystal violet staining based assay
|
[PMID: 33373820] |
| MDA-MB-231 | IC50 |
7 μM
Compound: Tamoxifen
|
Cytotoxicity against ER-negative human MDA-MB-231 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
Cytotoxicity against ER-negative human MDA-MB-231 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
|
[PMID: 33373820] |
| MDA-MB-231 | IC50 |
14.5 μM
Compound: Tamoxifen
|
Antiproliferative activity against human MDA-MB-231 cells by MTT reduction assay
Antiproliferative activity against human MDA-MB-231 cells by MTT reduction assay
|
[PMID: 33421712] |
| MDA-MB-231 | IC50 |
15.01 μM
Compound: Tamoxifen
|
Cytotoxicity against human MDA-MB-231 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay
Cytotoxicity against human MDA-MB-231 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay
|
[PMID: 33894490] |
| MDA-MB-231 | IC50 |
>50 μM
Compound: Tamoxifen
|
Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell growth incubated for 48 hrs by CCK8 assay
Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell growth incubated for 48 hrs by CCK8 assay
|
[PMID: 34022716] |
| MDA-MB-231 | IC50 |
10.11 μM
Compound: TAM
|
Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
|
[PMID: 34153643] |
| MDA-MB-231 | IC50 |
14.94 μM
Compound: 1
|
Antiproliferative activity against human MDA-MB-231 cells assessed as cell viability after 24 hrs by MTT assay
Antiproliferative activity against human MDA-MB-231 cells assessed as cell viability after 24 hrs by MTT assay
|
[PMID: 35276362] |
| MDA-MB-231 | GI50 |
0.24 μM
Compound: Tamoxifen
|
Growth inhibition of human MDA-MB-231 cells measured after 48 hrs by SRB assay
Growth inhibition of human MDA-MB-231 cells measured after 48 hrs by SRB assay
|
[PMID: 36577217] |
| MDA-MB-231 | IC50 |
<1000 μM
Compound: Tamoxifen
|
Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth incubated for 72 hrs by Hoechst 33342/propidium iodide staining based fluorescence analysis
Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth incubated for 72 hrs by Hoechst 33342/propidium iodide staining based fluorescence analysis
|
[PMID: 36603398] |
| MDA-MB-231 | IC50 |
18.48 μM
Compound: Tamoxifen
|
Cytotoxicity against human MDA-MB-231 cells incubated for 72 hrs by Sulphorhodamine assay
Cytotoxicity against human MDA-MB-231 cells incubated for 72 hrs by Sulphorhodamine assay
|
[PMID: 37146520] |
| MDA-MB-231 | IC50 |
25 μM
Compound: 1; TMX
|
Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth
Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth
|
[PMID: 37484572] |
| MDA-MB-231 | IC50 |
25.575 μM
Compound: 1; TMX
|
Anticancer activity against human MDA-MB-231 cells assessed as inhibition of cell growth incubated for 48 hrs by CVDK-8 method
Anticancer activity against human MDA-MB-231 cells assessed as inhibition of cell growth incubated for 48 hrs by CVDK-8 method
|
[PMID: 37484572] |
| MDA-MB-231 | IC50 |
30.848 μM
Compound: 1; TMX
|
Anticancer activity against human MDA-MB-231 cells assessed as inhibition of cell growth incubated for 24 hrs by CVDK-8 method
Anticancer activity against human MDA-MB-231 cells assessed as inhibition of cell growth incubated for 24 hrs by CVDK-8 method
|
[PMID: 37484572] |
| MDA-MB-231 | IC50 |
25.9 μM
Compound: TMX
|
Cytotoxicity against human MDA-MB-231 assessed as reduction in cell viability measured after 48 hrs by WST-1 assay
Cytotoxicity against human MDA-MB-231 assessed as reduction in cell viability measured after 48 hrs by WST-1 assay
|
[PMID: 38020071] |
| MDA-MB-231 | IC50 |
9.96 μM
Compound: TAM
|
Antiproliferative activity against estrogen receptor negative human MDA-MB-231 cells assessed as inhibition of cell viability by MTT assay
Antiproliferative activity against estrogen receptor negative human MDA-MB-231 cells assessed as inhibition of cell viability by MTT assay
|
[PMID: 38729318] |
| MDA-MB-231 | GI50 |
0.24 μM
Compound: Tamoxifen
|
Growth inhibition of human MDA-MB-231 cells measured after 48 hrs by SRB assay
Growth inhibition of human MDA-MB-231 cells measured after 48 hrs by SRB assay
|
[PMID: 38911170] |
| MDA-MB-231 | IC50 |
25.1 μM
Compound: Tamoxifen
|
Cytotoxicity against Homo sapiens (human) MDA-MB-231 cells assessed as inhibition of cell proliferation after 72 hr by MTT assay
Cytotoxicity against Homo sapiens (human) MDA-MB-231 cells assessed as inhibition of cell proliferation after 72 hr by MTT assay
|
10.1007/s00044-012-0391-5 |
| MDA-MB-231 | IC50 |
28 μM
Compound: Tamoxifen
|
In vitro inhibition of estrogen receptor negative MDA-MD-231 human mammary carcinoma cell proliferation
In vitro inhibition of estrogen receptor negative MDA-MD-231 human mammary carcinoma cell proliferation
|
10.1016/0960-894X(95)00381-3 |
| MDA-MB-231 | IC50 |
27 μM
Compound: Tam
|
Cytotoxicity against human ER negative MDA-MB-231 cells after 48 hrs by MTT assay
Cytotoxicity against human ER negative MDA-MB-231 cells after 48 hrs by MTT assay
|
10.1039/C4MD00289J |
| MDA-MB-435 | IC50 |
50 nM
Compound: Tamoxifen
|
Inhibition of MDA-MB-435 breast cancer cell proliferation
Inhibition of MDA-MB-435 breast cancer cell proliferation
|
[PMID: 14971899] |
| MDA-MB-435 | GI50 |
3.16 μM
Compound: TAM
|
Cytotoxicity against human MDA-MB-435 cells assessed as growth inhibition after 48 hrs by SRB assay
Cytotoxicity against human MDA-MB-435 cells assessed as growth inhibition after 48 hrs by SRB assay
|
[PMID: 26896706] |
| MDA-MB-435 | IC50 |
0.1 μM
Compound: Tamoxifen
|
Antiproliferative activity against human MDA-MB-435 cells
Antiproliferative activity against human MDA-MB-435 cells
|
[PMID: 33421712] |
| MDA-MB-435S | IC50 |
5.5 μM
Compound: Tamoxifen
|
Cytotoxicity against human MDA-MB-435S cells assessed as cell viability by MTT assay
Cytotoxicity against human MDA-MB-435S cells assessed as cell viability by MTT assay
|
[PMID: 26079090] |
| MDA-MB-436 | IC50 |
15.8 μM
Compound: TMX
|
Cytotoxicity against human MDA-MB-436 assessed as reduction in cell viability measured after 48 hrs by WST-1 assay
Cytotoxicity against human MDA-MB-436 assessed as reduction in cell viability measured after 48 hrs by WST-1 assay
|
[PMID: 38020071] |
| MDA-MB-453 | IC50 |
>5 μM
Compound: tamoxifen (TAM)
|
Inhibition of estrogen receptor negative MDA-MB-453 breast cancer cell proliferation with 10e-4 M estradiol
Inhibition of estrogen receptor negative MDA-MB-453 breast cancer cell proliferation with 10e-4 M estradiol
|
[PMID: 8784443] |
| MDA-MB-468 | GI50 |
2.5 μM
Compound: TAM
|
Cytotoxicity against human MDA-MB-468 cells assessed as growth inhibition after 48 hrs by SRB assay
Cytotoxicity against human MDA-MB-468 cells assessed as growth inhibition after 48 hrs by SRB assay
|
[PMID: 26896706] |
| MDA-MB-468 | IC50 |
14.99 μM
Compound: Tam
|
Cytotoxicity against human ER negative MDA-MB-468 cells after 48 hrs by MTT assay
Cytotoxicity against human ER negative MDA-MB-468 cells after 48 hrs by MTT assay
|
10.1039/C4MD00289J |
| MEL-JUSO | EC50 |
14.6 μM
Compound: TAM
|
Antiproliferative activity against human MelJuSo cells assessed as reduction in cell viability measured after 24 hrs by celltiter-blue assay
Antiproliferative activity against human MelJuSo cells assessed as reduction in cell viability measured after 24 hrs by celltiter-blue assay
|
[PMID: 31099568] |
| M-HeLa | IC50 |
28 μM
Compound: Tamoxifen
|
Antiproliferative activity against human M-HeLa cells by fluorescence based viable cell counting method
Antiproliferative activity against human M-HeLa cells by fluorescence based viable cell counting method
|
[PMID: 31610378] |
| M-HeLa | IC50 |
28 μM
Compound: Tamoxifen
|
Antiproliferative activity against human M-HeLa cells assessed as reduction in cell viability after 24 hrs by DAPI/propidium iodide staining based assay
Antiproliferative activity against human M-HeLa cells assessed as reduction in cell viability after 24 hrs by DAPI/propidium iodide staining based assay
|
[PMID: 31673312] |
| M-HeLa | IC50 |
28 μM
Compound: Tamoxifen
|
Cytotoxicity against human M-HeLa cells
Cytotoxicity against human M-HeLa cells
|
[PMID: 32386856] |
| M-HeLa | IC50 |
28 μM
Compound: Tmx
|
Anticancer activity against human HelaM cells assessed as cell growth inhibition measured after 24 hrs by DAPI and propidium iodide staining based assay
Anticancer activity against human HelaM cells assessed as cell growth inhibition measured after 24 hrs by DAPI and propidium iodide staining based assay
|
[PMID: 36481599] |
| MIA PaCa-2 | IC50 |
33.12 μM
Compound: Tam
|
Antiproliferative activity human MIAPaCa2 cells after 2 days by MTT assay
Antiproliferative activity human MIAPaCa2 cells after 2 days by MTT assay
|
[PMID: 25222876] |
| MOLT-4 | GI50 |
2.5 μM
Compound: TAM
|
Cytotoxicity against human MOLT4 cells assessed as growth inhibition after 48 hrs by SRB assay
Cytotoxicity against human MOLT4 cells assessed as growth inhibition after 48 hrs by SRB assay
|
[PMID: 26896706] |
| MRC5 | IC50 |
10.9 μM
Compound: TAM
|
Cytotoxicity against human MRC5 cells assessed as cell viability after 4 to 7 days by Alamar Blue staining based fluorometric analysis
Cytotoxicity against human MRC5 cells assessed as cell viability after 4 to 7 days by Alamar Blue staining based fluorometric analysis
|
[PMID: 26922226] |
| MRC5 | IC50 |
11.09 μM
Compound: Tamoxifen
|
Cytotoxicity against human MRC5 cells after 24 hrs by resazurin dye based assay
Cytotoxicity against human MRC5 cells after 24 hrs by resazurin dye based assay
|
[PMID: 30692024] |
| MRC5 | CC50 |
11.09 μM
Compound: Tamoxifen
|
Cytotoxicity against human MRC5 cells assessed as reduction in cell viability measured after 24 hrs by resazurin dye based fluorimetric assay
Cytotoxicity against human MRC5 cells assessed as reduction in cell viability measured after 24 hrs by resazurin dye based fluorimetric assay
|
[PMID: 30857749] |
| MRC5 | IC50 |
11.09 μM
Compound: Tamoxifen
|
Cytotoxicity in human MRC5 cells assessed as reduction in cell viability incubated for 24 hrs by resazurin-based cytotoxicity assay
Cytotoxicity in human MRC5 cells assessed as reduction in cell viability incubated for 24 hrs by resazurin-based cytotoxicity assay
|
[PMID: 30879839] |
| MRC5 | CC50 |
10 μM
Compound: Tamoxifen
|
Cytotoxicity against human MRC5 cells measured after 7 days by MTT assay
Cytotoxicity against human MRC5 cells measured after 7 days by MTT assay
|
[PMID: 33667089] |
| MRC5 | IC50 |
17.2 μM
Compound: Tamoxifen
|
Cytotoxicity against human MRC5 cells assessed as inhibition of cell growth measured after 72 hrs by resazurin staining based microscopic analysis
Cytotoxicity against human MRC5 cells assessed as inhibition of cell growth measured after 72 hrs by resazurin staining based microscopic analysis
|
[PMID: 36242986] |
| MSTO-211H | GI50 |
23.3 μM
Compound: 1
|
Antiproliferative activity against human MSTO-211H cells after 72 hrs by trypan blue assay
Antiproliferative activity against human MSTO-211H cells after 72 hrs by trypan blue assay
|
[PMID: 23735829] |
| MVLN | IC50 |
0.3 μM
Compound: Tam Z
|
Anti-estrogenicity for 50% inhibition of the MVLN cell luciferase activity due to 0.1 nM E2 (estradiol)
Anti-estrogenicity for 50% inhibition of the MVLN cell luciferase activity due to 0.1 nM E2 (estradiol)
|
[PMID: 9089332] |
| NCI/ADR-RES | IC50 |
2 μM
Compound: Tamoxifen
|
Inhibition of MCF-7/Adr breast cancer cell proliferation
Inhibition of MCF-7/Adr breast cancer cell proliferation
|
[PMID: 14971899] |
| NCI/ADR-RES | IC50 |
11.13 μM
Compound: Tamoxifen
|
Cytotoxicity against human MCF7/ADR cells after 48 hrs by MTT assay
Cytotoxicity against human MCF7/ADR cells after 48 hrs by MTT assay
|
[PMID: 23022281] |
| NCI-H460 | GI50 |
4.48 μM
Compound: Tamoxifen
|
Anticancer activity against human NCI-H460 cells after 24 hrs by SRB assay
Anticancer activity against human NCI-H460 cells after 24 hrs by SRB assay
|
[PMID: 19733085] |
| NIH3T3 | IC50 |
7.26 μM
Compound: 2
|
Cytotoxicity against mouse NIH/3T3 cells after 96 hrs by SRB assay
Cytotoxicity against mouse NIH/3T3 cells after 96 hrs by SRB assay
|
[PMID: 22749392] |
| NIH3T3 | IC50 |
7.26 μmol
Compound: 2
|
Cytotoxicity against mouse NIH/3T3 cells after 96 hrs by SRB assay
Cytotoxicity against mouse NIH/3T3 cells after 96 hrs by SRB assay
|
[PMID: 22749392] |
| NIH3T3 | IC50 |
11.4 μM
Compound: TAM
|
Antiproliferative activity against mouse NIH/3T3 cells after 48 hrs by MTT assay
Antiproliferative activity against mouse NIH/3T3 cells after 48 hrs by MTT assay
|
[PMID: 23287057] |
| NIH3T3 | IC50 |
>100 μM
Compound: Tam
|
Antiproliferative activity mouse NIH/3T3 cells after 2 days by MTT assay
Antiproliferative activity mouse NIH/3T3 cells after 2 days by MTT assay
|
[PMID: 25222876] |
| NIH3T3 | IC50 |
10.66 μg/mL
Compound: Tamoxifen
|
Phototoxicity against BALB/c mouse 3T3 cells assessed as reduction in cell viability preincubated for 1 hr followed by 5 J/cm2 irradiation and subsequent replacement of medium without compound and measured after 24 hrs by neutral red dye based assay
Phototoxicity against BALB/c mouse 3T3 cells assessed as reduction in cell viability preincubated for 1 hr followed by 5 J/cm2 irradiation and subsequent replacement of medium without compound and measured after 24 hrs by neutral red dye based assay
|
[PMID: 38128906] |
| NIH3T3 | IC50 |
13.03 μg/mL
Compound: Tamoxifen
|
Dark toxicity against BALB/c mouse 3T3 cells assessed as reduction in cell viability incubated for 1 hr by neutral red dye based assay
Dark toxicity against BALB/c mouse 3T3 cells assessed as reduction in cell viability incubated for 1 hr by neutral red dye based assay
|
[PMID: 38128906] |
| NIH-3T3-G185 | IC50 |
12.1 μM
Compound: Tamoxifen
|
TP_TRANSPORTER: inhibition of LDS-751 efflux in NIH-3T3-G185 cells
TP_TRANSPORTER: inhibition of LDS-751 efflux in NIH-3T3-G185 cells
|
[PMID: 11716514] |
| NIH-3T3-G185 | IC50 |
31.4 μM
Compound: Tamoxifen
|
TP_TRANSPORTER: inhibition of Rhodamine 123 efflux in NIH-3T3-G185 cells
TP_TRANSPORTER: inhibition of Rhodamine 123 efflux in NIH-3T3-G185 cells
|
[PMID: 11716514] |
| NIH-3T3-G185 | IC50 |
6.4 μM
Compound: Tamoxifen
|
TP_TRANSPORTER: inhibition of Daunorubicin efflux in NIH-3T3-G185 cells
TP_TRANSPORTER: inhibition of Daunorubicin efflux in NIH-3T3-G185 cells
|
[PMID: 11716514] |
| OVCAR-5 | GI50 |
32 μM
Compound: 1
|
Cytotoxicity against human OVCAR5 cells assessed as cell growth inhibition after 72 hrs by MTS assay
Cytotoxicity against human OVCAR5 cells assessed as cell growth inhibition after 72 hrs by MTS assay
|
[PMID: 27128175] |
| PANC-1 | GI50 |
0.15 μM
Compound: Tamoxifen
|
Cytotoxicity against human PANC1 cells
Cytotoxicity against human PANC1 cells
|
[PMID: 31200236] |
| PANC-1 | GI50 |
0.12 μM
Compound: Tamoxifen
|
Growth inhibition of human PANC1 cells
Growth inhibition of human PANC1 cells
|
[PMID: 31605865] |
| PC-3 | IC50 |
10 μM
Compound: TAM
|
Antiproliferative activity against human PC3 cells after 48 hrs by MTT assay
Antiproliferative activity against human PC3 cells after 48 hrs by MTT assay
|
[PMID: 23287057] |
| PC-3 | IC50 |
7 μM
Compound: Tamoxifen
|
Antiproliferative activity against human PC3 cells after 24 hrs by MTT assay
Antiproliferative activity against human PC3 cells after 24 hrs by MTT assay
|
[PMID: 24880230] |
| PC-3 | IC50 |
>40 μM
Compound: Tamoxifen
|
Antiproliferative activity against human PC3 cells
Antiproliferative activity against human PC3 cells
|
[PMID: 27155469] |
| PC-3 | IC50 |
>1000 nM
Compound: 7
|
Cytotoxicity against human PC-3 cells assessed as inhibition of cell growth measured after 72 hrs by MTT assay
Cytotoxicity against human PC-3 cells assessed as inhibition of cell growth measured after 72 hrs by MTT assay
|
[PMID: 33479633] |
| PC-3 | IC50 |
15.8 μM
Compound: TAM
|
Cytotoxicity against human PC-3 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
Cytotoxicity against human PC-3 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
|
[PMID: 34153643] |
| RAW264.7 | CC50 |
11.1 μM
Compound: Tamoxifen
|
Cytotoxicity against mouse RAW264.7 cells assessed as reduction in cell viability after 24 hrs by neutral red dye based assay
Cytotoxicity against mouse RAW264.7 cells assessed as reduction in cell viability after 24 hrs by neutral red dye based assay
|
[PMID: 31703818] |
| RAW264.7 | IC50 |
18.5 μM
Compound: Tamoxifen
|
Cytotoxicity against mouse RAW264.7 cells assessed as inhibition of cell growth measured after 72 hrs by resazurin staining based microscopic analysis
Cytotoxicity against mouse RAW264.7 cells assessed as inhibition of cell growth measured after 72 hrs by resazurin staining based microscopic analysis
|
[PMID: 36242986] |
| RAW264.7 | CC50 |
5.03 μM
Compound: Tamoxifen
|
Cytotoxicity against mouse RAW264.7 cells assessed as reduction of cell viability incubated for 72 hrs by Cell Titer-Glo assay
Cytotoxicity against mouse RAW264.7 cells assessed as reduction of cell viability incubated for 72 hrs by Cell Titer-Glo assay
|
[PMID: 37871508] |
| SH-SY5Y | IC50 |
20 μM
Compound: Tamoxifen
|
Inhibition of PKC in human SH-SY5Y cells assessed as inhibition of PMA-stimulated MARCKS phosphorylation preincubated for 1 hr followed by PMA-stimulation for 15 mins by Western blot analysis
Inhibition of PKC in human SH-SY5Y cells assessed as inhibition of PMA-stimulated MARCKS phosphorylation preincubated for 1 hr followed by PMA-stimulation for 15 mins by Western blot analysis
|
[PMID: 27647375] |
| SiHa | GI50 |
0.12 μM
Compound: Tamoxifen
|
Cytotoxicity against human SiHa cells
Cytotoxicity against human SiHa cells
|
[PMID: 31200236] |
| SiHa | GI50 |
0.12 μM
Compound: Tamoxifen
|
Growth inhibition of human SiHa cells
Growth inhibition of human SiHa cells
|
[PMID: 31605865] |
| SiHa | GI50 |
0.12 μM
Compound: Tamoxifen
|
Growth inhibition of human SiHa cells measured after 48 hrs by SRB assay
Growth inhibition of human SiHa cells measured after 48 hrs by SRB assay
|
[PMID: 36577217] |
| SK-BR-3 | ED50 |
5 μg/mL
Compound: TAM
|
Cytotoxicity against human SK-BR-3 cells expressing HER2 and lacking ER
Cytotoxicity against human SK-BR-3 cells expressing HER2 and lacking ER
|
[PMID: 16942038] |
| SK-BR-3 | ED50 |
5 μg/mL
Compound: TAM
|
Cytotoxicity against estrogen receptor deficient human SKBR3 cells overexpressing human epidermal growth factor receptor 2 after 72 hrs by SRB assay
Cytotoxicity against estrogen receptor deficient human SKBR3 cells overexpressing human epidermal growth factor receptor 2 after 72 hrs by SRB assay
|
[PMID: 19425534] |
| SK-BR-3 | GI50 |
12.5 μM
Compound: Tamoxifen
|
Cytotoxicity against human SKBR3 cells assessed as growth inhibition after 120 hrs by MTT assay
Cytotoxicity against human SKBR3 cells assessed as growth inhibition after 120 hrs by MTT assay
|
[PMID: 28152429] |
| SK-BR-3 | IC50 |
28.32 μM
Compound: Tamoxifen
|
Cytotoxicity against human SK-BR-3 cells after 48 hrs by MTT assay
Cytotoxicity against human SK-BR-3 cells after 48 hrs by MTT assay
|
[PMID: 33340662] |
| SK-BR-3 | IC50 |
<1000 μM
Compound: Tamoxifen
|
Antiproliferative activity against human SK-BR-3 cells assessed as inhibition of cell growth incubated for 72 hrs by Hoechst 33342/propidium iodide staining based fluorescence analysis
Antiproliferative activity against human SK-BR-3 cells assessed as inhibition of cell growth incubated for 72 hrs by Hoechst 33342/propidium iodide staining based fluorescence analysis
|
[PMID: 36603398] |
| SK-MEL-28 | IC50 |
1.86 μg/mL
Compound: Tomoxifen
|
Cytotoxicity against human SK-MEL-28 cells by alamar blue assay
Cytotoxicity against human SK-MEL-28 cells by alamar blue assay
|
[PMID: 11720540] |
| SK-OV-3 | GI50 |
6.4 μM
Compound: Tamoxifen
|
Anticancer activity against human SKOV3 cells after 24 hrs by SRB assay
Anticancer activity against human SKOV3 cells after 24 hrs by SRB assay
|
[PMID: 19733085] |
| SK-OV-3 | GI50 |
10 μM
Compound: TAM
|
Cytotoxicity against human SKOV3 cells assessed as growth inhibition after 48 hrs by SRB assay
Cytotoxicity against human SKOV3 cells assessed as growth inhibition after 48 hrs by SRB assay
|
[PMID: 26896706] |
| SNB-75 | GI50 |
5.01 μM
Compound: TAM
|
Cytotoxicity against human SNB75 cells assessed as growth inhibition after 48 hrs by SRB assay
Cytotoxicity against human SNB75 cells assessed as growth inhibition after 48 hrs by SRB assay
|
[PMID: 26896706] |
| SW-620 | ED50 |
4 μg/mL
Compound: TAM
|
Cytotoxicity against human SW620 cells
Cytotoxicity against human SW620 cells
|
[PMID: 16942038] |
| T47D | IC50 |
0.1 μM
Compound: Tamoxifen
|
Antiestrogenic activity in human T47D cells expressing estrogen receptor assessed as estrogen-dependent transcription by luciferase reporter gene assay
Antiestrogenic activity in human T47D cells expressing estrogen receptor assessed as estrogen-dependent transcription by luciferase reporter gene assay
|
[PMID: 19131248] |
| T47D | IC50 |
1 μM
Compound: Tamoxifen
|
Growth inhibition of human estrogen-dependent T47D cells after 72 hrs
Growth inhibition of human estrogen-dependent T47D cells after 72 hrs
|
[PMID: 19131248] |
| T47D | IC50 |
13 μM
Compound: TAM
|
Antiproliferative activity against human T47D cells after 48 hrs by MTT assay
Antiproliferative activity against human T47D cells after 48 hrs by MTT assay
|
[PMID: 23287057] |
| T47D | IC50 |
1.13 μM
Compound: Tamoxifen
|
Cytotoxicity against human T47D cells after 5 days
Cytotoxicity against human T47D cells after 5 days
|
[PMID: 23864928] |
| T47D | GI50 |
1.99 μM
Compound: TAM
|
Cytotoxicity against human T47D cells assessed as growth inhibition after 48 hrs by SRB assay
Cytotoxicity against human T47D cells assessed as growth inhibition after 48 hrs by SRB assay
|
[PMID: 26896706] |
| T47D | GI50 |
10.6 μM
Compound: Tamoxifen
|
Cytotoxicity against human T47D cells assessed as growth inhibition after 120 hrs by MTT assay
Cytotoxicity against human T47D cells assessed as growth inhibition after 120 hrs by MTT assay
|
[PMID: 28152429] |
| T47D | IC50 |
34.42 μM
Compound: Tamoxifen
|
Antiproliferative activity against human T47D cells after 24 hrs by MTT assay
Antiproliferative activity against human T47D cells after 24 hrs by MTT assay
|
[PMID: 30731397] |
| T47D | IC50 |
14.2 μM
Compound: Tamoxifen
|
Antiproliferative activity against human T47D cells by MTT reduction assay
Antiproliferative activity against human T47D cells by MTT reduction assay
|
[PMID: 33421712] |
| T47D | IC50 |
12.1 μM
Compound: Tamoxifen
|
Cytotoxicity against Homo sapiens (human) T47D cells assessed as inhibition of cell proliferation after 72 hr by MTT assay
Cytotoxicity against Homo sapiens (human) T47D cells assessed as inhibition of cell proliferation after 72 hr by MTT assay
|
10.1007/s00044-012-0391-5 |
| T47D | IC50 |
29.9 μM
Compound: Tam
|
Cytotoxicity against human T47D cells expressing ER after 48 hrs by MTT assay
Cytotoxicity against human T47D cells expressing ER after 48 hrs by MTT assay
|
10.1039/C4MD00289J |
| THP-1 | IC50 |
11.91 μM
Compound: Tamoxifen
|
Antiproliferative activity against human THP-1 cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay
Antiproliferative activity against human THP-1 cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay
|
[PMID: 31884407] |
| UO-31 | GI50 |
6.3 μM
Compound: TAM
|
Cytotoxicity against human UO31 cells assessed as growth inhibition after 48 hrs by SRB assay
Cytotoxicity against human UO31 cells assessed as growth inhibition after 48 hrs by SRB assay
|
[PMID: 26896706] |
| Vero | IC50 |
15.9 μM
Compound: Tamoxifen
|
Cytotoxicity against african green monkey Vero cells assessed as growth inhibition after 72 hrs by MTT assay
Cytotoxicity against african green monkey Vero cells assessed as growth inhibition after 72 hrs by MTT assay
|
[PMID: 23786452] |
| Vero | IC50 |
5.7 μM
Compound: Tamoxifen
|
Cytotoxicity against African green monkey Vero cells assessed as cell viability by MTT assay
Cytotoxicity against African green monkey Vero cells assessed as cell viability by MTT assay
|
[PMID: 26079090] |
| Vero | IC50 |
36.2 μM
Compound: Tamoxifen
|
Cytotoxicity against african green monkey Vero cells incubated for 72 hrs by Sulphorhodamine assay
Cytotoxicity against african green monkey Vero cells incubated for 72 hrs by Sulphorhodamine assay
|
[PMID: 37146520] |
| ZR-75-1 | ED50 |
3.6 μg/mL
Compound: TAM
|
Cytotoxicity against human ZR-75-1 cells expressing ER
Cytotoxicity against human ZR-75-1 cells expressing ER
|
[PMID: 16942038] |
Tamoxifen (ICI 47699) shows strong inhibition of MCF-7 cells (EC50=1.41 μM) and to a lesser extent the T47D cells (EC50=2.5 μM) but does not affect the MDA-MB-231 cells[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
| Species | Dose | Route | AUC0-∞ | Cmax | Half-life | Tmax | T1/2 | Bioavailability |
|---|---|---|---|---|---|---|---|---|
| Mice[12] | 10 mg/kg | p.o. | 25.1 ng/mL·h | 11.4 ng/mL | 2.0 h | 0.5 h | / | / |
| Mice[12] | 10 mg/kg | s.c. | 363 ng/mL·h | 43.4 ng/mL | 6.8 h | 1.0 h | / | / |
| Mice[12] | 20 mg/kg | p.o. | 104 ng/mL·h | 40.8 ng/mL | 7.6 h | 1.0 h | / | / |
| Mice[12] | 20 mg/kg | s.c. | 769 ng/mL·h | 49.4 ng/mL | 11.2 h | 4.0 h | / | / |
| Mice[12] | 4 mg/kg | p.o. | 3.8 ng/mL·h | 1.7 ng/mL | 1.0 h | 1.0 h | / | / |
| Mice[12] | 4 mg/kg | s.c. | 152 ng/mL·h | 20.5 ng/mL | 7.7 h | 2.0 h | / | / |
| Rat[13] | 10 mg/kg | p.o. | 2060 ng/mL·h | 126 ng/mL | / | 1.17 h | 11.2 h | 22.2 (absolute) % |
| Rat[13] | 2 mg/kg | i.v. | 1860 ng/mL·h | / | / | / | 9.0 h | 100 (absolute) % |
Administration: 75 mg/kg • i.p. • once daily for 5 days
(2) Administration methods: Common methods include intraperitoneal injection, and it can also be administered by oral gavage or subcutaneous injection. When performing multiple intraperitoneal injections, the injection sites should be alternated.
(3) Dosage: The dosage is 50-120 mg/kg, with 3-5 intraperitoneal injections, usually for 5 consecutive days. The dosage for pregnant mice and aged mice (over 6 months old) should be appropriately reduced. Tamoxifen can affect fetal development and parturition. For pregnant mice, the induction time should preferably be selected in the late pregnancy stage, and progesterone should be injected simultaneously to reduce the probability of miscarriage.
(4) Mice: Mice at 4-6 weeks old may be more sensitive (it is more effective in young mice than in old mice).
(5) Potential toxicity: Prolonged high-level Cre activity can cause potential toxicity. In addition, if an important functional gene is knocked out or using Homozygous Mice, it may also lead to the death of mice. Therefore, close observation should be carried out within one or two weeks after induction. If the mice show abnormalities, the causes need to be analyzed in a timely manner and the experimental plan should be adjusted.
(6) Control: Control group mice should be injected with an equal amount of the corn oil solution of Tamoxifen (using Tamoxifen in a genetic background without Cre recombinase) to rule out the influence of Tamoxifen itself.
(7) Detection window: The time window between Tamoxifen administration and the start of the experiment should be large enough, at least 7 days, to ensure that the Cre recombinase enters the nucleus and functions.
(8) Separate caging: Animals treated with Tamoxifen should be caged separately from untreated animals to avoid cross - contamination caused by behaviors such as animals licking the oily Tamoxifen suspension, grooming their fur, or coprophagy.
Administration: 45 mg/kg • i.p. • once daily for 7 days
(2) At the end of the experiment, the animals were euthanized by cervical dislocation under mild ether anesthesia. The blood samples were collected in heparinized centrifuge tubes and centrifuged to obtain serum. The abdomen was opened, and the liver was immediately dissected and removed. It was washed with ice-cold isotonic saline and blotted between two filter papers. The liver was wrapped in aluminum foil and stored at -80°C. A 10% (w/v) liver homogenate was prepared in ice-cold 0.1 M potassium phosphate buffer (pH 7.5) using an ultrasonicator.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 10540-29-1
-
Appearance Solid
-
Molecular Weight 371.51
-
Formula C26H29NO
-
Color White to off-white
-
SMILES
CC/C(C1=CC=CC=C1)=C(C2=CC=CC=C2)/C3=CC=C(C=C3)OCCN(C)C
-
Synonyms
ICI 47699; (Z)-Tamoxifen; trans-Tamoxifen
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
Publications (259)
-
Journal Impact Factor
-
Most Recent
-
Signal Transduct Target Ther
2023 Feb 3;8(1):51. PMID: 36732502 -
Science
2026 Jul 2;393(6806):eaef0825. PMID: 42391361 -
Science
Commensal-driven serotonin production modulates in vivo delivery of synthetic and viral vectors. [Abstract]2026 Mar 19;391(6791):eadu7686. PMID: 41855345 -
Cancer Cell
Single-cell screens identify ADAM12 as a fibroblast checkpoint impeding anti-tumor immunity. [Abstract]2026 Feb 9;44(2):424-442.e14. PMID: 41544628 -
Cancer Cell
2024 Nov 11;42(11):1955-1969.e7. PMID: 39532065
Tamoxifen purchased from MedChemExpress. Usage Cited in: Cancer Cell. 2024 Nov 11;42(11):1955-1969.e7. [Abstract]
Peripheral blood chimerism (%Cd45.2) in mice engrafted with WT (Cd45.1) and Flt3Frt-ITD (Cd45.2) cells following treatment with Tamoxifen (4 mg/mouse; p.o.) (red) or control (black).
Tamoxifen purchased from MedChemExpress. Usage Cited in: Cancer Cell. 2024 Nov 11;42(11):1955-1969.e7. [Abstract]
Flt3Frt-ITD (red), Dnmt3aLox-R878H-Flt3Frt-ITD (orange), and Npm1Frt-c-Flt3Frt-ITD (green) bone marrow was transplanted into lethally irradiated hosts. Kaplan-Meier survival plot following TAM (4 mg/mouse; p.o.).
Tamoxifen purchased from MedChemExpress. Usage Cited in: Cancer Cell. 2024 Nov 11;42(11):1955-1969.e7. [Abstract]
Bone marrow H&E from either control mice or after 7 days of TAM (4 mg/mouse; p.o.).
Tamoxifen purchased from MedChemExpress. Usage Cited in: Cancer Cell. 2024 Nov 11;42(11):1955-1969.e7. [Abstract]
Immunohistochemical staining on bone marrow for Ki67 (left) and phopsho-ERK1/2 (right) for untreated (top) and 7-day TAM (4 mg/mouse; p.o.) treated (bottom) Npm1Lox-C-Flt3GL-ITD mice.
-
Cell
Procr+ chondroprogenitors sense mechanical stimuli to govern articular cartilage maintenance and regeneration. [Abstract]2025 Sep 18;188(19):5194-5211.e16. PMID: 40695281 -
Cell
2025 May 29;188(11):3013-3029.e19. PMID: 40252640 -
Cell
2024 Sep 5;187(18):5064-5080.e14. PMID: 39089254 -
Cell
2022 Aug 4;185(16):3008-3024.e16. PMID: 35870449 -
Immunity
2024 Jan 9;57(1):106-123.e7. PMID: 38159573 -
Immunity
Microglia-derived PDGFB promotes neuronal potassium currents to suppress basal sympathetic tonicity and limit hypertension. [Abstract]2022 Aug 9;55(8):1466-1482.e9. PMID: 35863346 -
Immunity
Affinity-Restricted Memory B Cells Dominate Recall Responses to Heterologous Flaviviruses. [Abstract]2020 Nov 17;53(5):1078-1094.e7. PMID: 33010224
Tamoxifen purchased from MedChemExpress. Usage Cited in: Immunity. 2020 Nov 17;53(5):1078-1094.e7. [Abstract]
Frequency of TdTomato-labelled cells in TdT-Jchain mice treated with Tamoxifen (mice; 50 mg/kg; oral gavage; for two consecutive days) 14 and 15 days after WNV vaccination was analyzed by flow cytometry 13 days later (28 days after WNV vaccination) and compared to week 1 labeling.
-
Cell Res
2026 May 27. PMID: 42191977 -
Cell Res
Nonenzymatic lysine D-lactylation induced by glyoxalase II substrate SLG dampens inflammatory immune responses. [Abstract]2025 Feb;35(2):97-116. PMID: 39757301 -
Gut
IL-20 subfamily cytokines impair the oesophageal epithelial barrier by diminishing filaggrin in eosinophilic oesophagitis. [Abstract]2023 May;72(5):821-833. PMID: 35613844 -
Cancer Commun (Lond)
RNA m1A methyltransferase TRMT61A promotes colorectal tumorigenesis by enhancing ONECUT2 mRNA stability and is a potential therapeutic target. [Abstract]2025 Oct 16. PMID: 41103012 -
Cancer Commun (Lond)
Yap methylation-induced FGL1 expression suppresses anti-tumor immunity and promotes tumor progression in KRAS-driven lung adenocarcinoma. [Abstract]2024 Nov;44(11):1350-1373. PMID: 39340215 -
Sci Bull
Nuclear receptor ESRRA promotes ERα-positive breast cancer through dual action on super enhancers and promoters to regulate gene transcriptional programs. [Abstract]2025 Sep 29:S2095-9273(25)00984-3. PMID: 41111053 -
Nat Neurosci
GABA-dependent microglial elimination of inhibitory synapses underlies neuronal hyperexcitability in epilepsy. [Abstract]2025 Jul;28(7):1404-1417. PMID: 40425792 -
Cell Mol Immunol
SPT6 maintains epidermal homeostasis by inhibiting an NF-κB-positive feedback loop to prevent excessive inflammation. [Abstract]2026 May;23(5):471-490. PMID: 41922599 -
Cell Mol Immunol
An animal model of NLRC4-associated autoinflammation and infantile enterocolitis reveals novel therapeutic strategies. [Abstract]2025 Oct 20. PMID: 41116055 -
Cell Mol Immunol
Demyelination-derived lysophosphatidylserine promotes microglial dysfunction and neuropathology in a mouse model of Alzheimer's disease. [Abstract]2025 Feb;22(2):134-149. PMID: 39741193 -
Cell Mol Immunol
2024 Oct;21(10):1131-1144. PMID: 39030423 -
Nat Cell Biol
Spermidine mediates acetylhypusination of RIPK1 to suppress diabetes onset and progression. [Abstract]2024 Dec;26(12):2099-2114. PMID: 39511379
Tamoxifen purchased from MedChemExpress. Usage Cited in: Nat Cell Biol. 2024 Dec;26(12):2099-2114. [Abstract]
Tamoxifen (2 mg/day; i.p.; for 5 consecutive days) can effectively induce the removal of NAT1 in various tissues, including muscle, white adipose tissue, pancreas, and liver, in adult Nat1fl/fl;UBCcreERT2/+ mice and in Nat1fl/fl;UBCcreERT2/+;Ripk1D138N/D138N mice carrying a RIPK1 allele with an inactivation mutation.
-
Cancer Res
YAP1 Inhibition Induces Phenotype Switching of Cancer-Associated Fibroblasts to Tumor Suppressive in Prostate Cancer. [Abstract]2024 Nov 15;84(22):3728-3742. PMID: 39137404
Tamoxifen purchased from MedChemExpress. Usage Cited in: Cancer Res. 2024 Nov 15;84(22):3728-3742. [Abstract]
Schematic image of selective YAP1 depletion model on Cd248-CreERT2; Yap1flox/flox mice by using Tamoxifen (120 mg/kg/day; i.p. for 5 d).
-
Sci Immunol
DDX55 safeguards naïve T cell homeostasis by suppressing activation-promoting transposable elements. [Abstract]2025 Sep 5;10(111):eadq0457. PMID: 40911696 -
Sci Immunol
2025 Jul 11;10(109):eadu7962. PMID: 40644510 -
Circ Res
2025 Jan 17;136(2):e1-e19. PMID: 39655444 -
Nat Commun
Inhibition of MBTPS1 enhances antitumor immunity and potentiates anti-PD-1 immunotherapy. [Abstract]2025 Apr 30;16(1):4047. PMID: 40307212 -
Nat Commun
2025 Jan 30;16(1):1175. PMID: 39885146 -
Nat Commun
Mammalian SLC39A13 promotes ER/Golgi iron transport and iron homeostasis in multiple compartments. [Abstract]2024 Dec 30;15(1):10838. PMID: 39738060 -
Nat Commun
Mechanics-activated fibroblasts promote pulmonary group 2 innate lymphoid cell plasticity propelling silicosis progression. [Abstract]2024 Nov 12;15(1):9770. PMID: 39532893 -
Nat Commun
Astrocyte-derived clusterin disrupts glial physiology to obstruct remyelination in mouse models of demyelinating diseases. [Abstract]2024 Sep 6;15(1):7791. PMID: 39242637 -
Nat Commun
Alternations in inflammatory macrophage niche drive phenotypic and functional plasticity of Kupffer cells. [Abstract]2024 Oct 29;15(1):9337. PMID: 39472435 -
Cell Death Differ
TUFT1 stabilizes TGF-β receptor II protein and facilitates activation of hepatic stellate cells into metastasis-promoting myofibroblasts. [Abstract]2026 Jan 28. PMID: 41593321 -
Cell Death Differ
HDAC3 activates endothelial NLRP3 inflammasome and promotes atherosclerosis via inhibiting the acetylation of specificity protein 1. [Abstract]2025 Nov 26. PMID: 41299088 -
Cell Death Differ
FMRP regulation of STAT3-MYC signaling is critical for adult hippocampal neurogenesis and cognitive flexibility. [Abstract]2025 Jul 19. PMID: 40683950 -
Neuron
Oligodendrocyte-encoded lactate dehydrogenase A couples glycolysis to remyelination via protein lactylation. [Abstract]2026 Mar 16:S0896-6273(26)00137-6. PMID: 41844160 -
Bone Res
Osteopontin deficiency promotes cartilaginous endplate degeneration by enhancing the NF-κB signaling to recruit macrophages and activate the NLRP3 inflammasome. [Abstract]2024 Sep 6;12(1):53. PMID: 39242551 -
-
Autophagy
Mechanical stress-mediated ferritinophagy aggravates cartilage endplate degeneration via a PIEZO1-NCOA4-ZBP1 axis. [Abstract]2026 May 31:1-22. PMID: 42153663 -
Autophagy
2025 Sep 29:1-19. PMID: 40963239 -
Adv Sci (Weinh)
CD4+ Tregs Drive Post-Ischemic Sprouting Angiogenesis via Endothelial YY1/MAML1 Reactivation. [Abstract]2026 May 20:e18564. PMID: 42159401 -
Adv Sci (Weinh)
AXL Promotes Ischemic Myelin Repair Through Alleviating Myelin Debris Deposition and Lipid Droplets Accumulation. [Abstract]2026 Feb;13(10):e17825. PMID: 41524160 -
Adv Sci (Weinh)
Piezo1 Upregulation in Monocyte-Derived Macrophages Impairs Post-Myocardial Infarction Cardiac Repair via Defective Efferocytosis and Enhanced Ferroptosis. [Abstract]2025 Nov 10:e10991. PMID: 41214880 -
Adv Sci (Weinh)
2025 Oct 14:e15374. PMID: 41085070 -
Adv Sci (Weinh)
2025 Aug 4:e03972. PMID: 40755418 -
Adv Sci (Weinh)
2025 Aug 11:e02535. PMID: 40787892 -
Adv Sci (Weinh)
Targeting Rab7-Rilp Mediated Microlipophagy Alleviates Lipid Toxicity in Diabetic Cardiomyopathy. [Abstract]2024 Jun 5:e2401676. PMID: 38837607 -
J Clin Invest
Aging-dependent microglial heterogeneity worsens outcomes in models of traumatic brain injury. [Abstract]2026 Apr 2;136(12):e196112. PMID: 41926211 -
J Clin Invest
Ectopic B lymphocyte follicles exacerbate ischemic brain damage via MIF-CD74/CXCR4 and interferon signaling. [Abstract]2026 Mar 2;136(5):e196905. PMID: 41766668 -
J Clin Invest
Astrocyte-intrinsic signaling of chitinase-like protein CHI3L1 drives inflammation and amplifies demyelination in neuromyelitis optica. [Abstract]2026 Jan 2;136(1):e195506. PMID: 41480772 -
J Clin Invest
Excessive collagen type VII mediates pleural fibrosis via increasing extracellular matrix stiffness. [Abstract]2025 Oct 16:e188822. PMID: 41100460 -
J Clin Invest
2025 Jun 2;135(11):e184158. PMID: 40454481 -
J Clin Invest
Inhibition of aortic CX3CR1+ macrophages mitigates thoracic aortic aneurysm progression in Marfan syndrome in mice. [Abstract]2025 Jan 16;135(2):e178198. PMID: 39817456 -
Cardiovasc Res
METTL14 inhibits atherogenesis by epigenetically activating PPAR-α/γ transcription and fatty acid oxidation in VSMCs. [Abstract]2026 Mar 24:cvag069. PMID: 41873711 -
Theranostics
2026 Feb 4;16(8):4452-4470. PMID: 41695487 -
Cardiovasc Res
RBM24 regulates phenotypic switching of smooth muscle cell in vascular remodeling by stabilizing JAK2 mRNA. [Abstract]2025 Nov 11:cvaf219. PMID: 41216933 -
Cardiovasc Res
YY1 regulates vascular resistance and blood pressure dynamics through epigenetic control of m6A RNA modifications in VSMCs. [Abstract]2025 Aug 7:cvaf136. PMID: 40795179 -
Cardiovasc Res
METTL3-catalyzed m6A methylation facilitates the contribution of vascular smooth muscle cells to atherosclerosis. [Abstract]2025 May 6;121(4):568-584. PMID: 39977233 -
Theranostics
Rbm24/Notch1 signaling regulates adult neurogenesis in the subventricular zone and mediates Parkinson-associated olfactory dysfunction. [Abstract]2024 Aug 1;14(11):4499-4518. PMID: 39113792 -
Cardiovasc Res
Cardiomyocyte βII spectrin plays a critical role in maintaining cardiac function by regulating mitochondrial respiratory function. [Abstract]2024 Jun 4:cvae116. PMID: 38832923 -
Theranostics
A novel lncRNA linc-AhRA negatively regulates innate antiviral response in murine microglia upon neurotropic herpesvirus infection. [Abstract]2021 Sep 21;11(19):9623-9651. PMID: 34646390 -
Theranostics
Dysfunction of estrogen-related receptor alpha-dependent hepatic VLDL secretion contributes to sex disparity in NAFLD/NASH development. [Abstract]2020 Aug 29;10(24):10874-10891. PMID: 33042259
Tamoxifen purchased from MedChemExpress. Usage Cited in: Theranostics. 2020 Aug 29;10(24):10874-10891. [Abstract]
Representative fields, intracellular TG contents and secreted TG of female C57BL/6 mice hepatocytes treated with C29, Tamoxifen (20 μM; 36 h), Toremifene and 4-OHT. LDs were labeled with Nile Red (red).
Tamoxifen purchased from MedChemExpress. Usage Cited in: Theranostics. 2020 Aug 29;10(24):10874-10891. [Abstract]
Representative images of liver tissue (top), sections stained with Oil Red O (bottom) and liver TG levels from Ad-ERRα or Ad-Ctrl-injected female mice treated with TMX (100 mg/kg; p.o. for 5 days).
-
Theranostics
Rbm24 modulates adult skeletal muscle regeneration via regulation of alternative splicing. [Abstract]2020 Sep 11;10(24):11159-11177. PMID: 33042276 -
-
Nucleic Acids Res
Super-enhancer-controlled positive feedback loop BRD4/ERα-RET-ERα promotes ERα-positive breast cancer. [Abstract]2022 Oct 14;50(18):10230-10248. PMID: 36124682 -
J Adv Res
SIRT7 facilitates ferroptosis resistance of melanocytes via activating the SMAD3-ATF3-GPX4 signaling pathway in vitiligo. [Abstract]2025 Jul 12:S2090-1232(25)00545-4. PMID: 40659088 -
J Adv Res
GDF11 protects against mitochondrial-dysfunction-dependent NLRP3 inflammasome activation to attenuate osteoarthritis. [Abstract]2024 Aug 3:S2090-1232(24)00323-0. PMID: 39103049 -
J Adv Res
Mechanical overloading induces GPX4-regulated chondrocyte ferroptosis in osteoarthritis via Piezo1 channel facilitated calcium influx. [Abstract]2022 Nov:41:63-75. PMID: 36328754 -
Biomaterials
Black phosphorus nanosheets activate tumor immunity of glioblastoma by modulating the expression of the immunosuppressive molecule PD-L1. [Abstract]2024 Dec 27:317:123062. PMID: 39736218 -
J Exp Clin Cancer Res
The immunotoxin targeting PRLR increases tamoxifen sensitivity and enhances the efficacy of chemotherapy in breast cancer. [Abstract]2024 Jun 20;43(1):173. PMID: 38898487 -
Sci Adv
Quantitative prediction of siRNA complexation by ionizable drugs enables their codelivery in nanoparticles. [Abstract]2026 Jun 12;12(24):eaed2731. PMID: 42284421 -
Sci Adv
Beta2 adrenergic receptor-mediated abnormal myelopoiesis drives neuroinflammation in aged patients with traumatic brain injury. [Abstract]2024 Jul 19;10(29):eadp5239. PMID: 39028822 -
Sci Adv
ZBTB21 suppresses CRE-mediated transcription to impair synaptic function in Down syndrome. [Abstract]2024 Jul 5;10(27):eadm7373. PMID: 38959316 -
Sci Adv
Microglial Ffar4 deficiency promotes cognitive impairment in the context of metabolic syndrome. [Abstract]2024 Feb 2;10(5):eadj7813. PMID: 38306420 -
Sci Adv
TERT accelerates BRAF mutant-induced thyroid cancer dedifferentiation and progression by regulating ribosome biogenesis. [Abstract]2023 Sep;9(35):eadg7125. PMID: 37647391 -
Redox Biol
Inhibition of ferroptosis and iron accumulation alleviates pulmonary fibrosis in a bleomycin model. [Abstract]2022 Nov:57:102509. PMID: 36302319
Tamoxifen purchased from MedChemExpress. Usage Cited in: Redox Biol. 2022 Nov:57:102509. [Abstract]
Expression of TFRC in primary fibroblasts from TFRCflox/flox and TFRC−/− mice was assessed by western blot after 5 days of Tamoxifen intraperitoneal injection and 7 days of waiting.
-
Biomark Res
PAQR5 drives the malignant progression and shapes the immunosuppressive microenvironment of hepatocellular carcinoma by activating the NF-κB signaling. [Abstract]2025 May 7;13(1):70. PMID: 40336138 -
J Hazard Mater
Fibroblast-derived CXCL14 aggravates crystalline silica-induced pulmonary fibrosis by mediating polarization and recruitment of interstitial macrophages. [Abstract]2023 Oct 15:460:132489. PMID: 37688871 -
Research (Wash D C)
Regulating Integrin β1 to Restore Gonadotropin-Releasing Hormone-Tanycyte Unit Function in Polycystic Ovary Syndrome-Related Hypothalamic Dysregulation. [Abstract]2025 Feb 19:8:0619. PMID: 39975575 -
Cell Rep Med
CAN-Scan: A multi-omic phenotype-driven precision oncology platform identifies prognostic biomarkers of therapy response for colorectal cancer. [Abstract]2025 Apr 2:102053. PMID: 40187357 -
J Neuroinflammation
Hyperglycemia impairs microglia responding to retinal vasculopathy via enhanced norepinephrine-ADRB2 signaling. [Abstract]2025 Dec 8. PMID: 41361454 -
J Neuroinflammation
Microglial NLRC5 drives lysosomal dysfunction to disrupt autophagic flux and promote post-stroke neuroinflammation. [Abstract]2025 Oct 31;22(1):253. PMID: 41174779 -
Mol Psychiatry
Anterior insular cortex regulates depression-like and ASD-like behaviors via the differential contribution of two subsets of microglia. [Abstract]2025 Aug 6. PMID: 40770435 -
J Neuroinflammation
Prolactin deficiency drives diabetes-associated cognitive dysfunction by inducing microglia-mediated synaptic loss. [Abstract]2024 Nov 14;21(1):295. PMID: 39543619 -
Cancer Lett
JAML promotes the antitumor role of tumor-resident CD8+ T cells by facilitating their innate-like function in human lung cancer. [Abstract]2024 May 28:590:216839. PMID: 38570084 -
Cancer Lett
DHCR7 promotes lymph node metastasis in cervical cancer through cholesterol reprogramming-mediated activation of the KANK4/PI3K/AKT axis and VEGF-C secretion. [Abstract]2024 Mar 1:584:216609. PMID: 38211648 -
Int J Biol Sci
The SGK3/GSK3β/β-catenin signaling promotes breast cancer stemness and confers resistance to alpelisib therapy. [Abstract]2025 Mar 19;21(6):2462-2475. PMID: 40303291 -
Cell Death Dis
Endothelial IRE1 signaling maintains blood-brain barrier integrity and limits neuroinflammation after traumatic brain injury. [Abstract]2026 Feb 9. PMID: 41663365 -
Cell Death Dis
RAD51B-EZH2 axis as a potential therapeutic target for TNBC through cell fate conversion. [Abstract]2025 Nov 30. PMID: 41318657 -
Cell Death Dis
ATP6AP1 promotes cell proliferation and tamoxifen resistance in luminal breast cancer by inducing autophagy. [Abstract]2025 Mar 25;16(1):201. PMID: 40133274 -
Cell Death Dis
Deletion of Mettl3 in mesenchymal stem cells promotes acute myeloid leukemia resistance to chemotherapy. [Abstract]2023 Dec 5;14(12):796. PMID: 38052820 -
Cell Death Dis
Cardiac-specific CGI-58 deficiency activates the ER stress pathway to promote heart failure in mice. [Abstract]2021 Oct 26;12(11):1003. PMID: 34702801 -
Sci China Life Sci
Downregulation of METTL3 enhances TRADD-mediated apoptosis in inflammatory bowel disease. [Abstract]2025 Jul;68(7):2010-2027. PMID: 40347213 -
Proc Natl Acad Sci U S A
Bone marrow-derived IGF-1 orchestrates maintenance and regeneration of the adult skeleton. [Abstract]2023 Jan 3;120(1):e2203779120. PMID: 36577075 -
Proc Natl Acad Sci U S A
2022 Oct 4;119(40):e2204716119. PMID: 36161929 -
Proc Natl Acad Sci U S A
DDX11 loss causes replication stress and pharmacologically exploitable DNA repair defects. [Abstract]2021 Apr 27;118(17):e2024258118. PMID: 33879618 -
Cell Commun Signal
Estrogen receptor α-NOTCH1 axis enhances basal stem-like cells and epithelial-mesenchymal transition phenotypes in prostate cancer. [Abstract]2019 May 23;17(1):50. PMID: 31122254
Tamoxifen purchased from MedChemExpress. Usage Cited in: Cell Commun Signal. 2019 May 23;17(1):50. [Abstract]
Tamoxifen inhibits the growth and metastasis of prostate tumors in vivo. Western blot analysis of the indicated proteins in prostate primary tumors tissues.
-
Dev Cell
A pathological role of O-GlcNAcylation-driven TR11B production and function in lung adenocarcinoma. [Abstract]2025 Sep 3:S1534-5807(25)00530-1. PMID: 40930100 -
Dev Cell
FGD5 in basal cells induces CXCL14 secretion that initiates a feedback loop to promote murine mammary epithelial growth and differentiation. [Abstract]2024 May 25:S1534-5807(24)00324-1. PMID: 38821057 -
Phytomedicine
Tongmai Huazheng mixture attenuates adenomyosis by inducing ferroptosis through suppression of the JAK2/STAT3 signaling pathway. [Abstract]2025 Dec 28:150:157748. PMID: 41477983 -
Phytomedicine
Paris polyphylla ethanol extract and polyphyllin I ameliorate adenomyosis by inhibiting epithelial-mesenchymal transition. [Abstract]2024 May:127:155461. PMID: 38452697 -
ACS Appl Mater Interfaces
A Self-Delivering Oxygen Modulator for Breast Cancer Immunotherapy via Pyroptosis Induction and PD-L1 Degradation. [Abstract]2025 Aug 27;17(34):48029-48043. PMID: 40796528 -
Chemosphere
2020 Jan;239:124705. PMID: 31479913 -
-
Neoplasia
SLC31A1 promotes chemoresistance through inducing CPT1A-mediated fatty acid oxidation in ER-positive breast cancer. [Abstract]2025 Feb 3:61:101125. PMID: 39904115 -
Br J Pharmacol
Microglial forkhead box O3a deficiency attenuates LPS-induced neuro-inflammation and depressive-like behaviour through regulating the expression of peroxisome proliferator-activated receptor-γ. [Abstract]2024 Oct;181(20):3908-3925. PMID: 38881194 -
NPJ Breast Cancer
2025 Jul 17;11(1):73. PMID: 40675988 -
Brain Behav Immun
2024 Jan:115:705-717. PMID: 37992789 -
NPJ Breast Cancer
Estrogen receptor inhibition mediates radiosensitization of ER-positive breast cancer models. [Abstract]2022 Mar 10;8(1):31. PMID: 35273179 -
Oncogene
2025 Sep 16:10.1038/s41388-025-03571-1. PMID: 40957950 -
Stem Cell Res Ther
Adipose-derived stem cells attenuate rheumatoid arthritis by restoring CX3CR1+ synovial lining macrophage barrier. [Abstract]2025 Mar 5;16(1):111. PMID: 40038808 -
Cell Rep
2026 May 28;45(6):117471. PMID: 42213774 -
Cell Rep
Paracrine stimulation of brown adipose tissue vascularization by adipocyte O-GlcNAc signaling. [Abstract]2025 Dec 11;44(12):116678. PMID: 41385373 -
Cell Rep
The xCT/CD98 complex suppresses ferroptosis in pan-cancer via a non-canonical RACK1-mediated iron homeostasis pathway. [Abstract]2025 Nov 25;44(11):116563. PMID: 41252251 -
Cell Rep
2025 Aug 5;44(8):116112. PMID: 40773347 -
Arch Toxicol
Fibroblast EGFR signaling mediates ricin toxin-induced acute lung injury via EGR1/CXCL1 axis. [Abstract]2025 May 3. PMID: 40317338 -
Cell Rep
Maternal phthalates exposure promotes neural stem cell differentiation into phagocytic astrocytes and synapse engulfment via IRE1α/XBP1s pathway. [Abstract]2025 Jan 2;44(1):115126. PMID: 39752254 -
Cell Rep
Astrocyte-derived CHI3L1 signaling impairs neurogenesis and cognition in the demyelinated hippocampus. [Abstract]2024 May 10;43(5):114226. PMID: 38733586 -
Cell Rep
A microglial activation cascade across cortical regions underlies secondary mechanical hypersensitivity to amputation. [Abstract]2024 Feb 17;43(2):113804. PMID: 38368612 -
Cell Rep
RORα is required for expansion and memory maintenance of ILC1s via a lymph node-liver axis. [Abstract]2024 Feb 15;43(2):113786. PMID: 38363684 -
Cell Rep
CDKL5 deficiency in adult glutamatergic neurons alters synaptic activity and causes spontaneous seizures via TrkB signaling. [Abstract]2023 Sep 30;42(10):113202. PMID: 37777961 -
Cell Rep
2023 Sep 19;42(10):113158. PMID: 37733588 -
Br J Cancer
Spatial molecular analyses reveal key features associated with response to KN026 in advanced HER2-positive breast cancer. [Abstract]2025 Dec 9. PMID: 41366063 -
Br J Cancer
Androgen and oestrogen receptor co-expression determines the efficacy of hormone receptor-mediated radiosensitisation in breast cancer. [Abstract]2022 Sep;127(5):927-936. PMID: 35618789 -
J Med Chem
Screening and Reverse-Engineering of Estrogen Receptor Ligands as Potent Pan-Filovirus Inhibitors. [Abstract]2020 Oct 8;63(19):11085-11099. PMID: 32886512 -
Clin Transl Med
2020 Jan;10(1):137-150. PMID: 32508033
Tamoxifen purchased from MedChemExpress. Usage Cited in: Clin Transl Med. 2020 Jan;10(1):137-150. [Abstract]
Different transmission of MAPK8/FoxO signaling pathway in breast cancer cells (MCF-7, T47D, ZR-75, and MDA-MB-231) and liver cells (LO2) exposed to TAM (Tamoxifen).
-
Transl Psychiatry
Microglia-mediated inflammation and synaptic pruning contribute to sleep deprivation-induced mania in a sex-specific manner. [Abstract]2025 Aug 15;15(1):285. PMID: 40817224 -
Cell Mol Life Sci
Selenium-SelK-GPX4 axis protects nucleus pulposus cells against mechanical overloading-induced ferroptosis and attenuates senescence of intervertebral disc. [Abstract]2024 Jan 22;81(1):49. PMID: 38252317 -
Cell Mol Life Sci
Loss of Kmt2c in vivo leads to EMT, mitochondrial dysfunction and improved response to lapatinib in breast cancer. [Abstract]2023 Mar 18;80(4):100. PMID: 36933062 -
Cancer Cell Int
2024 Dec 27;24(1):433. PMID: 39731167 -
J Bone Miner Res
Single cell RNA sequencing shows that cells expressing Sox9 postnatally populate most skeletal lineages in mouse bone. [Abstract]2025 Mar 26:zjaf043. PMID: 40143416 -
Front Immunol
Development of a customizable mouse backbone spectral flow cytometry panel to delineate immune cell populations in normal and tumor tissues. [Abstract]2024 Mar 27:15:1374943. PMID: 38605953 -
Transl Res
Dach1 deficiency drives alveolar epithelium apoptosis in pulmonary fibrosis via modulating C-Jun/Bim activity. [Abstract]2023 Jul:257:54-65. PMID: 36754276 -
Front Immunol
Analysis of Mononuclear Phagocytes Disclosed the Establishment Processes of Two Macrophage Subsets in the Adult Murine Kidney. [Abstract]2022 Mar 10;13:805420. PMID: 35359928 -
Neurosci Bull
Neuronal and Glial YAP/TAZ in the Spinal Cord Contribute to the Development of Bone Cancer Pain in Mice. [Abstract]2026 Mar 22. PMID: 41866450 -
Neurosci Bull
Endothelial Cell Integrin α6 Regulates Vascular Remodeling Through the PI3K/Akt-eNOS-VEGFA Axis After Stroke. [Abstract]2025 May 2. PMID: 40316875 -
Atherosclerosis
Nicotine induces m6A-modified eNOS dysregulation to aggravate endothelial injury in male mice. [Abstract]2025 Dec:411:120558. PMID: 41192190 -
J Invest Dermatol
2023 Dec;143(12):2366-2377.e7. PMID: 37394057 -
Biochem Pharmacol
Targeting neuropilin-1 attenuates 4-hydroxytamoxifen-induced stemness and sensitizes ERα-re-expressing TNBC to tamoxifen. [Abstract]2026 Jun 12;251(Pt 2):118163. PMID: 42285368 -
Biochem Pharmacol
Mutant NPM1-regulated estrogen signaling promotes leukemia cell survival by upregulating HGF and represents a therapeutic vulnerability. [Abstract]2026 May:247:117796. PMID: 41679667 -
Cell Prolif
SOX30 Governs Synaptonemal Complex Assembly and Homologous Recombination in Male Meiosis. [Abstract]2025 Dec 30:e70158. PMID: 41467312 -
Biochem Pharmacol
2025 Oct:240:117107. PMID: 40619010 -
Cell Prolif
MCL restrained ROS/AKT/ASAH1 pathway to therapy tamoxifen resistance breast cancer by stabilizing NRF2. [Abstract]2024 Jun 26:e13700. PMID: 38924190 -
Biochem Pharmacol
MICAL-L2, as an estrogen-responsive gene, is involved in ER-positive breast cancer cell progression and tamoxifen sensitivity via the AKT/mTOR pathway. [Abstract]2024 May 9:225:116256. PMID: 38729448 -
Breast Cancer Res
UCHL1 contributes to insensitivity to endocrine therapy in triple-negative breast cancer by deubiquitinating and stabilizing KLF5. [Abstract]2024 Mar 11;26(1):44. PMID: 38468288 -
Cell Prolif
Type H vessel/platelet-derived growth factor receptor β+ perivascular cell disintegration is involved in vascular injury and bone loss in radiation-induced bone damage. [Abstract]2023 Jul;56(7):e13406. PMID: 36694343 -
Biochem Pharmacol
A protein-fragment complementation assay reveals that celastrol and gambogic acid suppress ERα mutants in breast cancer. [Abstract]2021 Jun:188:114583. PMID: 33915156 -
Cell Prolif
Direct inhibitory effect on viral entry of influenza A and SARS-CoV-2 viruses by azithromycin. [Abstract]2021 Jan;54(1):e12953. PMID: 33211371 -
Pharmaceutics
Drug Repurposing for the Identification of Compounds with Anti-SARS-CoV-2 Capability via Multiple Targets. [Abstract]2022 Jan 12;14(1):176. PMID: 35057070 -
J Ethnopharmacol
The modified Zuojin formula (SQQT) associates ILC2-linked JAK-2/STAT5/c-Myc cascade and gastric metaplasia regression. [Abstract]2026 May 10:362:121345. PMID: 41663001 -
Chem Biol Interact
Vitamin D inhibits tamoxifen-induced non-alcoholic fatty liver disease through a nonclassical estrogen receptor/liver X receptor pathway. [Abstract]2024 Feb 1:389:110865. PMID: 38191086 -
J Ethnopharmacol
Combining transcriptomics and network pharmacology to reveal the mechanism of zuojin capsule improving spasmolytic polypeptide-expressing metaplasia. [Abstract]2024 Jan 10;318(Pt B):117075. PMID: 37625606 -
Chem Biol Interact
Fatostatin inhibits SREBP2-mediated cholesterol uptake via LDLR against selective estrogen receptor α modulator-induced hepatic lipid accumulation. [Abstract]2022 Sep 25:365:110091. PMID: 35944649 -
Biomacromolecules
Noncovalent Surface Locking of Mesoporous Silica Nanoparticles for Exceptionally High Hydrophobic Drug Loading and Enhanced Colloidal Stability. [Abstract]2015 Sep 14;16(9):2701-14. PMID: 26200587 -
Cells
A Comprehensive Adenoid Cystic Carcinoma-Derived Organoid Platform for Disease Modeling and Drug Screening Captures Interpatient Heterogeneity. [Abstract]2026 Feb 23;15(4):383. PMID: 41744826 -
Glia
Targeted Inhibition of MEGF10-Mediated Astrogliosis Reduces Glial Scar Formation and Promotes Neurofunction Recovery in Mice After Stroke. [Abstract]2026 Jun;74(6):e70159. PMID: 41999081 -
Life Sci
A protective role of ECSIT in chemotherapy-induced intestinal mucositis by maintaining Lgr5+ intestinal stem cells and gut homeostasis. [Abstract]2026 Mar 15:389:124236. PMID: 41611204 -
Glia
2025 Jul 28. PMID: 40719051 -
Glia
2024 Feb;72(2):396-410. PMID: 37909251 -
J Clin Endocrinol Metab
2021 Apr 23;106(5):1410-1426. PMID: 33524147 -
CNS Neurosci Ther
SIX2-Mediated Microglial M2 Polarization and Exosomal miR-3470b Delivery Protect Dopaminergic Neurons in Parkinson's Disease. [Abstract]2026 Feb;32(2):e70756. PMID: 41700504 -
PLoS Pathog
CK2 derived from brain microvascular endothelial cells induces astrocyte inflammatory response in Escherichia coli-induced meningitis. [Abstract]2025 Sep 10;21(9):e1013464. PMID: 40929057 -
Int J Mol Sci
HER2-Driven Breast Cancer: Role of the Chaperonin HSP90 in Modulating Response to Trastuzumab-Based Therapeutic Combinations. [Abstract]2025 Jul 9;26(14):6593. PMID: 40724844 -
PLoS Pathog
Disrupting the OTUD4-USP7 deubiquitinase complex to suppress herpesvirus replication: a novel antiviral strategy. [Abstract]2025 Apr 10;21(4):e1013052. PMID: 40208866 -
Int J Mol Sci
Tamoxifen Exerts Anticancer Effects on Pituitary Adenoma Progression via Inducing Cell Apoptosis and Inhibiting Cell Migration. [Abstract]2022 Feb 28;23(5):2664. PMID: 35269804 -
Pharmaceuticals (Basel)
Development and Application of an UPLC-MS/MS Method for Simultaneous Quantification of Abemaciclib and Tamoxifen with Their Active Metabolites in Rat Plasma: Application to a Pharmacokinetic Study. [Abstract]2026 May 19;19(5):795. PMID: 42198468 -
Pharmaceuticals (Basel)
Refined Jianpi Huayu Jiedu Decoction Attenuates TAM-Induced Spasmolytic Polypeptide-Expressing Metaplasia (SPEM) by Modulating LCN2-Associated Mitochondrial Dysfunction. [Abstract]2026 Apr 24;19(5):667. PMID: 42198341 -
Int Immunopharmacol
Hexokinase 2 deficiency protects against sepsis-associated lung injury via suppressing the NF-κB signaling pathway. [Abstract]2026 Jun 20:185:117023. PMID: 42322859 -
Bioorg Chem
A novel ERα-targeted hydrophobic tag degrader, overcomes tamoxifen resistance via unfolded protein response-induced apoptosis and homologous recombination repair inhibition in breast cancer. [Abstract]2026 Jun 18:180:110129. PMID: 42348942 -
Int Immunopharmacol
The immunoregulator β-glucan produces antidepressant effects through microglia-mobilized astrocytic P2Y1R-BDNF signaling in the dentate gyrus. [Abstract]2025 Sep 6:165:115494. PMID: 40915186 -
Int Immunopharmacol
ATP citrate lyase ablation hampers exocrine regeneration via TLR4/NF-kappaB signaling after acute pancreatitis in mice. [Abstract]2024 Oct 31;143(Pt 3):113485. PMID: 39486178 -
mBio
Genome-Wide CRISPR-Cas9 Screen Identifies SMCHD1 as a Restriction Factor for Herpesviruses. [Abstract]2023 Apr 25;14(2):e0054923. PMID: 37010434 -
Neuropharmacology
GPR139-mediated cholinergic circuit from the medial septum to the ventral hippocampal CA3 modulates cognitive impairment in Alzheimer's disease. [Abstract]2026 Nov 1:298:111043. PMID: 42218995 -
Cancers (Basel)
BRD4 Inhibition as a Strategy to Prolong the Response to Standard of Care in Estrogen Receptor-Positive Breast Cancer. [Abstract]2023 Aug 11;15(16):4066. PMID: 37627092 -
Cancers (Basel)
Loss of cIAP1 in Endothelial Cells Limits Metastatic Extravasation through Tumor-Derived Lymphotoxin Alpha. [Abstract]2021 Feb 3;13(4):599. PMID: 33546280 -
Aquat Toxicol
Is acyl-CoA cholesterol acyltransferase 2 the enzyme responsible for the esterification of okadaic acid in bivalves?. [Abstract]2026 Jun:295:107814. PMID: 41935504 -
Exp Gerontol
Hepcidin inhibits osteoclast differentiation to alleviate osteoporosis by modulating the p53/miR-34a/Trem2 axis. [Abstract]2026 Jan:213:112994. PMID: 41386388 -
Exp Neurol
Oligodendrocyte lineage cell-specific GPR17/Gelsolin signaling regulates remyelination and cognitive recovery after subarachnoid hemorrhage. [Abstract]2026 Sep:403:115819. PMID: 42107622 -
J Cell Mol Med
Microglial FoxO3a deficiency ameliorates ferroptosis-induced brain injury of intracerebral haemorrhage via regulating autophagy and heme oxygenase-1. [Abstract]2024 Jan;28(1):e18007. PMID: 37890842 -
J Cell Mol Med
Tamoxifen inhibits cell proliferation by impaired glucose metabolism in gallbladder cancer. [Abstract]2020 Jan;24(2):1599-1613. PMID: 31782270 -
iScience
2025 Sep 10;28(10):113536. PMID: 41069851 -
J Neurosci
2024 Jun 19:e2192232024. PMID: 38897723 -
Prog Neuropsychopharmacol Biol Psychiatry
Microglial HMGB2 mediates neuroinflammation and brain damage in Cx3cr1-creERT2 epileptic mice through astrocyte-derived CCL2. [Abstract]2026 Jun 20:147:111763. PMID: 42218973 -
J Biol Chem
Caveolin-1 deficiency improved glucose metabolism via modulation of β-cell autophagy in high-fat diet-fed mice. [Abstract]2026 Jun;302(6):111480. PMID: 42031171 -
Biomedicines
Caveolin-1 Modulates Islet Amyloid Polypeptide Expression Through Interaction with TXNIP in Murine Pancreatic β-Cells. [Abstract]2026 Jun 15;14(6):1344. PMID: 42351772 -
JOR Spine
PIEZO1-Primary Cilia Axis Mediates Compressive Stress-Induced Growth Plate Degeneration and Ossification in Adolescent Idiopathic Scoliosis. [Abstract]2025 Nov 4;8(4):e70133. PMID: 41194970 -
Sci Rep
Impact of prenatal Di(2-ethylhexyl) phthalate exposure on pubertal development in female offspring rats: A focus on ERα-Mediated IGF-1/NKB crosstalk in the hypothalamus. [Abstract]2025 Jul 1;15(1):22255. PMID: 40595203 -
J Biol Chem
Downregulation of the splicing regulator NSRP1 confers resistance to CDK4/6 inhibitors via activation of interferon signaling in breast cancer. [Abstract]2024 Dec 10:108070. PMID: 39667501 -
Mol Cell Biochem
Endothelium Piezo1 deletion alleviates experimental varicose veins by attenuating perivenous inflammation. [Abstract]2025 Apr;480(4):2423-2435. PMID: 39249600 -
Cell Signal
Rap1GAP exacerbates myocardial infarction by regulating the AMPK/SIRT1/NF-κB signaling pathway. [Abstract]2024 May:117:111080. PMID: 38320624 -
Neurobiol Stress
Microglial SIRT6 confers protection against neuroinflammation-associated depression through NRF2-HO1 signaling. [Abstract]2026 Mar 21:42:100804. PMID: 41938092 -
Heliyon
Citrus polymethoxyflavones degrade estrogen receptor-alpha (ERα) and combine with tamoxifen for the treatment of estrogen receptor-positive breast cancer. [Abstract]2024 Jun 14;10(12):e33104. PMID: 39022050 -
Mol Med Rep
Mechanotransducer Piezo1 drives ventilator‑induced lung injury in lung epithelial cells via the calcineurin/NFATc3 pathway. [Abstract]2026 Jun;33(6):183. PMID: 42059278 -
Med Oncol
Ursolic acid affects autophagy and apoptosis of breast cancer through PLK1 via AKT/mTOR signaling pathway. [Abstract]2025 Jul 21;42(8):358. PMID: 40691672 -
Viruses
Autophagy Deregulation in HIV-1-Infected Cells Increases Extracellular Vesicle Release and Contributes to TLR3 Activation. [Abstract]2024 Apr 20;16(4):643. PMID: 38675983 -
RNA Biol
Rbm24 regulates inner-ear-specific alternative splicing and is essential for maintaining auditory and motor coordination. [Abstract]2020 Sep 20;1-13. PMID: 32887533 -
Biotechnol J
Engineering a Membrane-Anchored CreER Recombinase With Reduced Basal Activity for In Vitro Recombination. [Abstract]2026 May;21(5):e70236. PMID: 42116754 -
Cardiovasc Drugs Ther
E3 Ubiquitin Ligase UBR5 Aggravates Cardiac Hypertrophy Via Inhibiting Nrf2/HO-1 Pathway. [Abstract]2026 Mar 13. PMID: 41824182 -
Naunyn Schmiedebergs Arch Pharmacol
ML385 increases ferroptosis via inhibiting Nrf2/HO-1 pathway to enhances the sensitivity of MCF-7 TAMR to tamoxifen. [Abstract]2025 May 28. PMID: 40425765 -
Naunyn Schmiedebergs Arch Pharmacol
Overexpression of KIF2C amplifies tamoxifen resistance and lung metastasis of breast cancer through PLK1/C-Myc pathway. [Abstract]2025 Mar 18. PMID: 40100379 -
Cardiovasc Drugs Ther
2024 Apr;38(2):237-252. PMID: 36350487 -
J Pharm Biomed Anal
Screening method of mildronate and over 300 doping agents by reversed-phase liquid chromatography-high resolution mass spectrometry. [Abstract]2021 Feb 20:195:113870. PMID: 33453569 -
Breast Cancer Res Treat
Monopolar spindle 1 contributes to tamoxifen resistance in breast cancer through phosphorylation of estrogen receptor α. [Abstract]2023 Dec;202(3):595-606. PMID: 37695401 -
Bioorg Med Chem
A novel selective estrogen receptor degrader induces cell cycle arrest in breast cancer via ERα degradation and the autophagy-lysosome pathway. [Abstract]2023 Mar 15:82:117235. PMID: 36905762 -
Oral Dis
DDX5 Alleviates Temporomandibular Joint Osteoarthritis via TNF-Induced NF-κB Signaling Pathway. [Abstract]2025 Jul;31(7):2229-2242. PMID: 40013619 -
Int J Biochem Cell Biol
Tamoxifen upregulates the peroxisomal β-oxidation enzyme Enoyl CoA hydratase and 3-hydroxyacyl CoA hydratase ameliorating hepatic lipid accumulation in mice. [Abstract]2024 May 9:172:106585. PMID: 38734232 -
J Chromatogr B Analyt Technol Biomed Life Sci
Simultaneous determination of 11 oral targeted antineoplastic drugs and 2 active metabolites by LC-MS/MS in human plasma and its application to therapeutic drug monitoring in cancer patients. [Abstract]2024 Apr 15:1237:124100. PMID: 38547701 -
Front Genet
Genome-wide analysis of the FOXA1 transcriptional regulatory network identifies super enhancer associated LncRNAs in tamoxifen resistance. [Abstract]2022 Sep 20:13:992444. PMID: 36204307 -
-
PLoS One
Response Gene to Complement 32 promotes cell proliferation and tamoxifen resistance in breast cancer via elevated FoxM1 expression. [Abstract]2025 Jul 28;20(7):e0328698. PMID: 40720499 -
Hear Res
Chromatin and genomic instability in the cochlea contributing to age-related hearing loss: Insights from in vitro and in vivo models. [Abstract]2026 Aug:478:109691. PMID: 42263393 -
Chin J Integr Med
Curcumin Inhibits Fibroblast Differentiation and Epithelial-Mesenchymal Transition to Alleviate Adenomyosis through TGF-β1/Smad3 Pathway. [Abstract]2026 Jan 15. PMID: 41540162 -
Pharmacol Biochem Behav
Intranasal LAG3 antibody infusion induces microglia-dependent antidepressant effect by mobilizing astrocytic P2Y1R-mediated BDNF synthesis in the hippocampus. [Abstract]2025 Dec:257:174114. PMID: 41106438 -
J Steroid Biochem Mol Biol
OBHSA, a novel selective estrogen receptor degrader, overcomes tamoxifen resistance through cell cycle arrest and unfolded protein response-mediated apoptosis in breast cancer. [Abstract]2024 Aug 13:106599. PMID: 39147211 -
Biochem Biophys Res Commun
Tamoxifen promotes myogenic differentiation and skeletal muscle regeneration via activation of the GRP94. [Abstract]2026 Aug 20:827:154022. PMID: 42208231 -
Biochem Biophys Res Commun
SHED aggregation-released extracellular vesicles rejuvenate Gli1+ cells and improve diabetic wound healing. [Abstract]2025 Sep 1:777:152327. PMID: 40651366 -
Oncol Lett
Functional analysis of the effects of propofol on tamoxifen‑resistant breast cancer cells: Insights into transcriptional regulation. [Abstract]2025 Feb 21;29(4):194. PMID: 40041408 -
Biochem Biophys Res Commun
Neutrophils suppress osteogenic differentiation of Gli1+ stem cells via neutrophil extracellular traps and contribute to bone loss in periodontitis. [Abstract]2024 Oct 28:737:150916. PMID: 39489114 -
Biochim Biophys Acta Gen Subj
MFN2-mediated mitochondrial fusion facilitates acute hypobaric hypoxia-induced cardiac dysfunction by increasing glucose catabolism and ROS production. [Abstract]2023 Sep;1867(9):130413. PMID: 37331409 -
Biochem Biophys Res Commun
Combinatorial screening of a panel of FDA-approved drugs identifies several candidates with anti-Ebola activities. [Abstract]2020 Feb 19;522(4):862-868. PMID: 31806372 -
Toxicol Res (Camb)
Tamoxifen induced hepatic steatosis in high-fat feeding rats through SIRT1-Foxo1 suppression and LXR-SREBP1c activation. [Abstract]2022 Jul 22;11(4):673-682. PMID: 36051666 -
Am J Transl Res
Evaluation of the safety and tolerability of tamoxifen for ischemia-incited renal injury in mice. [Abstract]2018 Jul 15;10(7):2184-2194. PMID: 30093955 -
Cureus
Hsa-miR-181a-5p Enhances the Chemosensitivity of Breast Cancer Cells to Tamoxifen by Regulation of the OSBPL3/RAS Signaling Pathway. [Abstract]2025 Oct 20;17(10):e94996. PMID: 41267704 -
-
-
eGastroenterology
2026 Mar 31;4(1):e100348. PMID: 41948149 -
-
-
-
-
-
-
bioRxiv
Restoration of Spermatogenesis is Dependent on Activation of a SPRY4-ERK Checkpoint Following Germline Stem Cell Damage. [Abstract]2025 Oct 14:2025.10.12.681919. PMID: 41279276 -
bioRxiv
Controlled Delivery of a Neurotrophic Factor in the Adult Mouse Brain Using Engineered Microglia. [Abstract]2025 Oct 7:2025.10.06.680702. PMID: 41279766 -
-
-
-
-
-
-
-
-
-
-
-
-
-
-
bioRxiv
2023 Mar 15:2023.03.14.532677. PMID: 36993187 -
-
-
-
-
-
-
Res Sq
Sex differences in viral entry protein expression, host responses to SARS-CoV-2, and in vitro responses to sex steroid hormone treatment in COVID-19. [Abstract]2020 Dec 31:rs.3.rs-100914. PMID: 33173861 -
Solvent & Solubility
Ethanol : 50 mg/mL (134.59 mM; Need ultrasonic)
DMSO : 13.46 mg/mL (36.23 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
For the following dissolution methods, please prepare the working solution directly:
It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: Corn Oil
Solubility: 20 mg/mL (53.83 mM); Clear solution; Need ultrasonic
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL. * In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Protocol
Mice[3]
Seven-week old TmcsMed1-/- mice and the wild-type littermates are then administered Tamoxifen intraperitoneally at a daily dose of 65 mg/kg body weight for 5 days and then killed at selected intervals after initiation of Tamoxifen treatment. For each experiment 3 to 5 mice for control and csMed1-/- are used. To obtain survival curve 41 csMed1-/- and 41 csMed1fl/fl mice are used. Thirteen TmcsMed-/- mice and the same number of littermates are used for the survival curve experiments using Tamoxifen inducible model. The specific criteria for animal euthanasia included absence of food or water intake, slow or no mobility, weak or absence of heart beat, absence of palpitation of the chest as well as absence of respiratory movement.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Purity & Documentation
-
Data Sheet (292 KB)
-
SDS (701 KB)
- English - EN (701 KB)
- Français - FR (701 KB)
- Deutsch - DE (701 KB)
- Norwegian - NO (701 KB)
- Español - ES (701 KB)
- Swedish - SV (701 KB)
- Italian - IT (701 KB)
- Korean - KR (701 KB)
- Portuguese - PT (701 KB)
-
Handling Instructions (2659 KB)
References
[1]. Osborne CK. Tamoxifen in the treatment of breast cancer. N Engl J Med. 1998 Nov 26;339(22):1609-18. [Content Brief]
[2]. Hawariah A, et al. In vitro response of human breast cancer cell lines to the growth-inhibitory effects of styrylpyrone derivative (SPD) and assessment of its antiestrogenicity. Anticancer Res. 1998 Nov-Dec;18(6A):4383-6. [Content Brief]
[3]. Jun Nagai, et al. Hyperactivity with Disrupted Attention by Activation of an Astrocyte Synaptogenic Cue. Cell. 2019 May 16;177(5):1280-1292.e20. [Content Brief]
[4]. Zhao R, et al. Tamoxifen enhances the Hsp90 molecular chaperone ATPase activity. PLoS One. 2010 Apr 1;5(4):e9934. [Content Brief]
[5]. Kedjouar B, et al. Molecular characterization of the microsomal tamoxifen binding site. J Biol Chem. 2004 Aug 6;279(32):34048-61. [Content Brief]
[6]. Feil S, et, al. Inducible Cre mice. Methods Mol Biol. 2009;530:343-63. [Content Brief]
[7]. Kim H, et al. Mouse Cre-LoxP system: general principles to determine tissue-specific roles of target genes. Lab Anim Res. 2018 Dec;34(4):147-159. [Content Brief]
[8]. Bi Q, et al. Microglia-derived PDGFB promotes neuronal potassium currents to suppress basal sympathetic tonicity and limit hypertension. Immunity. 2022 Aug 9;55(8):1466-1482.e9. [Content Brief]
[9]. Chen MY, et al. A review of tamoxifen administration regimen optimization for Cre/loxp system in mouse bone study. Biomed Pharmacother. 2023 Sep;165:115045. [Content Brief]
[10]. El-Beshbishy HA. Hepatoprotective effect of green tea (Camellia sinensis) extract against tamoxifen-induced liver injury in rats. J Biochem Mol Biol. 2005 Sep 30;38(5):563-70. [Content Brief]
[11]. El-Beshbishy H A. The effect of dimethyl dimethoxy biphenyl dicarboxylate (DDB) against tamoxifen-induced liver injury in rats: DDB use is curative or protective[J]. BMB Reports, 2005, 38(3): 300-306. [Content Brief]
[12]. Reid JM, et al. Pharmacokinetics of endoxifen and tamoxifen in female mice: implications for comparative in vivo activity studies. Cancer Chemother Pharmacol. 2014 Dec;74(6):1271-8. [Content Brief]
[13]. Kim CS, et al. Effects of silybinin on the pharmacokinetics of tamoxifen and its active metabolite, 4-hydroxytamoxifen in rats. Anticancer Res. 2010 Jan;30(1):79-85. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO / Ethanol | 1 mM | 2.6917 mL | 13.4586 mL | 26.9172 mL | 67.2929 mL |
| 5 mM | 0.5383 mL | 2.6917 mL | 5.3834 mL | 13.4586 mL | |
| 10 mM | 0.2692 mL | 1.3459 mL | 2.6917 mL | 6.7293 mL | |
| 15 mM | 0.1794 mL | 0.8972 mL | 1.7945 mL | 4.4862 mL | |
| 20 mM | 0.1346 mL | 0.6729 mL | 1.3459 mL | 3.3646 mL | |
| 25 mM | 0.1077 mL | 0.5383 mL | 1.0767 mL | 2.6917 mL | |
| 30 mM | 0.0897 mL | 0.4486 mL | 0.8972 mL | 2.2431 mL | |
| Ethanol | 40 mM | 0.0673 mL | 0.3365 mL | 0.6729 mL | 1.6823 mL |
| 50 mM | 0.0538 mL | 0.2692 mL | 0.5383 mL | 1.3459 mL | |
| 60 mM | 0.0449 mL | 0.2243 mL | 0.4486 mL | 1.1215 mL | |
| 80 mM | 0.0336 mL | 0.1682 mL | 0.3365 mL | 0.8412 mL | |
| 100 mM | 0.0269 mL | 0.1346 mL | 0.2692 mL | 0.6729 mL |